🔗

Mappings

MONDO

MONDO:0005754 epilepsy with generalized tonic-clonic seizures

MONDO:0005754 carries "epilepsy with generalized tonic-clonic seizures alone" and "EGTCA" as EXACT synonyms and cross-references Orphanet:698005, the Orphanet concept for this ILAE syndrome. The MONDO label is the shorter form, so the entry name and the term label deliberately differ.

👪

Inheritance

1

Polygenic susceptibility HP:0010982

EGTCA is heritable but not Mendelian. Liability is distributed across many common variants of small effect together with rarer variants in ion channel and neurotransmitter receptor genes shared across the idiopathic generalized epilepsies. Relatives of an EGTCA proband who are affected typically have some other generalized epilepsy phenotype rather than EGTCA itself, which is the expected behavior of a shared polygenic liability rather than syndrome-specific transmission. Routine single-gene testing is correspondingly not part of clinical evaluation.

Polygenic inheritance

Show evidence (2 references)

PMID:37653029 SUPPORT Human Clinical

"suggesting that the signals are primarily driven by polygenicity"

The consortium's own reading of its linkage-disequilibrium score regression intercepts is that the generalized epilepsy association signal is polygenic rather than driven by a few large-effect loci, which is the architecture this inheritance block asserts.

PMID:19191339 SUPPORT Human Clinical

"However, the incomplete segregation of the mutations among affected members and the transmission by unaffected parents suggests that these CLCN2 mutations alone are not sufficient to induce epilepsy."

A worked demonstration of non-Mendelian behavior in the leading candidate gene: variants that do not segregate with disease and are transmitted by unaffected parents are susceptibility factors, not causative alleles.

?

Discussions and Knowledge Gaps

3

Why does a shared cortico-thalamocortical mechanism produce generalized tonic-clonic seizures alone in EGTCA, but absence or myoclonic seizures in its sibling syndromes?

KNOWLEDGE GAP OPEN egtca_seizure_type_divergence

Attached to

pathophysiology#Recruitment of Motor Systems into Tonic-Clonic Output

The four idiopathic generalized epilepsy syndromes are curated as sharing a polygenic thalamocortical mechanism, yet they are separated clinically by seizure type alone. No mechanistic account was identified during curation that explains why the same class of network abnormality yields convulsive output alone here and absence or myoclonus elsewhere. The entry therefore asserts a difference in network engagement without specifying it, and this node is the honest location of that gap.

Proposed experiments

Cross-syndrome ictal network comparison

egtca_cross_syndrome_network_imaging

Compare ictal and interictal network dynamics across EGTCA, juvenile absence epilepsy, and juvenile myoclonic epilepsy cohorts using one shared EEG-fMRI or MEG protocol, testing whether motor-system recruitment differs at the point of seizure onset rather than only in clinical output.

Adequately powered EGTCA-stratified GWAS

egtca_powered_subtype_gwas

Syndrome-stratified genetic analysis at sample sizes large enough to detect an EGTCA-specific locus, given that the 2023 ILAE meta-analysis was underpowered for this syndrome at n = 499.

Does the sodium-channel-blocker aggravation caution that applies across the idiopathic generalized epilepsies actually apply to EGTCA, where absence and myoclonic seizures are absent by definition?

KNOWLEDGE GAP OPEN egtca_sodium_channel_blocker_caution

Attached to

pathophysiology#Recurrent Unprovoked Generalized Tonic-Clonic Seizures

The evidence base for aggravation by carbamazepine and oxcarbazepine concerns myoclonic and absence seizures. In the oxcarbazepine series the effect on generalized tonic-clonic seizures was explicitly described as less dramatic, with no worsening in half the patients. Since EGTCA patients have no myoclonic or absence seizures to aggravate, the standard blanket caution may not transfer, but no EGTCA-specific study was identified either way. The entry records the uncertainty rather than repeating the generalization or asserting safety.

Show evidence (2 references)

PMID:15461683 SUPPORT INDIRECT Human Clinical

"The effects of OXC on GTCSs were less dramatic, with no worsening in frequency in three and a slight increase in three."

Shows that the aggravation signal is much weaker for generalized tonic-clonic seizures than for the myoclonic and absence seizures that drive the caution. Graded INDIRECT because the series contained no EGTCA patients, so this bounds the inference rather than resolving it.

PMID:15461683 SUPPORT Human Clinical

"Aggravation consisted of a clear aggravation of myoclonic jerks (five cases) or de novo myoclonic jerks (one case)."

Identifies the seizure types actually aggravated, none of which occur in EGTCA by definition, which is the basis for questioning the transfer.

Can absence-epilepsy rodent models be used as mechanistic evidence for EGTCA, when they reproduce spike-wave discharge with behavioral arrest rather than the awakening-triggered convulsive phenotype that defines the syndrome?

HUMAN MODEL MISMATCH OPEN egtca_absence_model_mismatch

Attached to

pathophysiology#Cortico-Thalamocortical Excitation-Inhibition Imbalance

The rodent models that underpin thalamocortical hypersynchrony theory are absence models producing spike-wave discharge with behavioral arrest, and none reproduces either the generalized-tonic-clonic-alone seizure output or the awakening-linked circadian pattern. Their evidence therefore bears on the shared network mechanism, not on what makes EGTCA a distinct syndrome. This entry deliberately cites no model-organism evidence for any node, which is why the mismatch is recorded here rather than attached to a citation.

Proposed experiments

Circadian convulsive-phenotype screen in GGE rodent lines

egtca_rodent_circadian_convulsive_screen

Characterize whether any existing genetic generalized epilepsy rodent line shows convulsive seizures clustering around the wake transition, and if so whether the circadian gating is separable from the underlying spike-wave mechanism.

⚙

Pathophysiology

8

Polygenic Susceptibility to Generalized Epilepsy

Susceptibility is conferred by many common variants of individually small effect together with rarer variants in genes encoding neuronal ion channels and neurotransmitter receptors, in particular voltage-gated calcium and chloride channels and GABA-A receptor subunits. No single gene is necessary or sufficient. The net effect is a lowered seizure threshold in cortico-thalamocortical circuits rather than a discrete molecular lesion, which is why the node is a distributed liability rather than a named mutation.

Neuron CL:0000540

Regulation of Membrane Potential GO:0042391 ⚠ ABNORMAL Chemical Synaptic Transmission GO:0007268 ⚠ ABNORMAL

Downstream

Cortico-Thalamocortical Excitation-Inhibition Imbalance

Show evidence (2 references)

PMID:37653029 SUPPORT Human Clinical

"Our 'GGE' meta-analysis uncovered a total of 25 independent genome-wide significant signals across 22 loci, of which 13 loci are new."

Establishes a many-loci common-variant architecture for genetic generalized epilepsy, the class to which EGTCA belongs, which is the distributed liability this node models.

PMID:37653029 SUPPORT Human Clinical

"We did not find any genome-wide significant loci for JAE (n = 671), GTCSA (n = 499)"

The syndrome-stratified analysis found no EGTCA-specific locus at the available sample size. This is an absence of evidence at n = 499 rather than evidence that no such locus exists; it supports the polygenic framing while bounding how confidently any particular gene can be attached to this syndrome.

Cortico-Thalamocortical Excitation-Inhibition Imbalance

The susceptibility alleles shift the balance between glutamatergic excitation and GABAergic inhibition within reciprocally connected cortical and thalamic populations toward net excitation. The thalamic reticular nucleus, whose GABAergic output paces thalamocortical relay neurons, is the inhibitory element whose dysfunction is most consistently implicated across the idiopathic generalized epilepsies.

GABAergic Neuron CL:0000617 Thalamic Relay Neuron CL:4023068

GABA Signaling Pathway GO:0007214 ↓ DECREASED

Thalamic Reticular Nucleus UBERON:0001903 Cerebral Cortex UBERON:0000956

Downstream

Generalized Hypersynchronous Discharge

Show evidence (2 references)

PMID:28752060 SUPPORT INDIRECT Human Clinical

"As interactions between thalamic sub-regions are indirect and mediated by the inhibitory thalamic reticular nucleus (TRN), the results suggest abnormal TRN function in patients with IGE"

Human EEG-fMRI evidence implicating the inhibitory thalamic reticular nucleus in idiopathic generalized epilepsy. Graded INDIRECT because the cohort is IGE-wide rather than EGTCA-specific, and because the TRN inference is indirect, drawn from intra-thalamic connectivity rather than measured directly.

PMID:38165295 SUPPORT INDIRECT Other

"Genetic, electrophysiologic, and neuroimaging studies provide insights into pathophysiology, including overlaps and differences from focal epilepsies."

Supports a network-level rather than lesional pathophysiology for the IGE class. Graded INDIRECT, and evidence_source OTHER, because this is a review synthesizing across syndromes rather than primary EGTCA data.

Generalized Hypersynchronous Discharge

Net excitatory bias permits large populations of cortical and thalamic neurons to fire in phase, producing the bilaterally synchronous generalized spike-wave and polyspike-wave discharges that are the electrographic signature of the syndrome. Between discharges the background is normal, which is what separates this from the encephalopathic generalized epilepsies.

Cortical Pyramidal Neuron CL:0000598 Corticothalamic Projection Neuron CL:4023013

Regulation of Membrane Potential GO:0042391 ⚠ ABNORMAL

Downstream

Recruitment of Motor Systems into Tonic-Clonic Output

Show evidence (2 references)

PMID:21269293 SUPPORT INDIRECT Human Clinical

"Although GSWDs are the result of highly synchronized activity in the thalamocortical network, EEG without GSWDs is believed to represent normal brain activity."

States both halves of this node's claim: the discharges reflect highly synchronized thalamocortical activity, and the network is otherwise normal between them. Graded INDIRECT because the study population is IGE-wide rather than EGTCA-specific.

PMID:21269293 SUPPORT Human Clinical

"The results underscore the paroxysmal nature of GSWDs: Although GSWDs are characterized by highly synchronized activity in the thalamocortical network, the functional connectivity in areas involved during GSWDs does not demonstrate abnormality in GSWD-free periods."

Supports modeling the hypersynchrony as a paroxysmal event on an otherwise normal network rather than a continuously abnormal state, which is why this node sits downstream of a susceptibility node rather than describing a persistent lesion.

Sleep-Wake State Gating of Seizure Threshold

The distinctive feature of EGTCA is not that seizures occur but when. The transition out of sleep, and sleep deprivation preceding it, transiently lower the threshold at which the hyperexcitable network converts into a clinical seizure, concentrating seizures in the hour or two after awakening independent of clock time. This node is deliberately modeled as a modulator acting on seizure generation rather than as a step in the causal chain, because it changes the probability and timing of the output without being required to produce it.

Circadian Sleep/Wake Cycle GO:0042745

Downstream

Recruitment of Motor Systems into Tonic-Clonic Output

Show evidence (3 references)

PMID:10996562 SUPPORT Human Clinical

"Awakening epilepsy (AE) is an age related syndrome of idiopathic generalized epilepsy (IGE) characterized by generalized tonic clonic seizures (GTCS) occurring predominantly on awakening (independent of the time of day) or at leisure time (almost at evening)."

The defining description of the awakening-linked seizure timing by the clinician who delineated the syndrome, and the basis for treating sleep-wake state as a distinct modulating input.

PMID:10996562 SUPPORT Human Clinical

"The common denominator of external seizures precipitating influences is lack of sleep."

Identifies sleep deprivation as the unifying precipitant, which is the threshold-lowering mechanism this node asserts.

PMID:24632482 SUPPORT INDIRECT Human Clinical

"Patients with idiopathic generalized epilepsy seemed to be more sensitive to seizures during awakening and sleep deprivation"

Independent clinic-cohort confirmation that awakening and sleep deprivation are differentially potent precipitants in idiopathic generalized epilepsy. Graded INDIRECT because the comparison is across broad epilepsy categories rather than within EGTCA, and the authors themselves hedge with "seemed to be".

Catamenial Gating of Seizure Threshold

A second state-gating input, parallel to the sleep-wake one. In some patients seizures cluster with the menstrual cycle, and catamenial seizures are one of only two features that independently predicted drug resistance in the largest ILAE-criteria cohort. It is modeled as a modulator on seizure generation for the same reason as the sleep-wake node: it changes when and how readily the hyperexcitable network converts to a clinical seizure without being required to produce one.

Downstream

Recruitment of Motor Systems into Tonic-Clonic Output

Show evidence (1 reference)

PMID:37872695 SUPPORT Human Clinical

"Catamenial seizures and morning predominance of generalized tonic-clonic seizures (GTCS) independently predicted drug resistance at the last visit according to multivariable logistic regression."

Establishes catamenial seizures as an independent prognostic factor in EGTCA, which is what justifies modeling menstrual-cycle gating as its own node. The same sentence is the main reason the sleep-wake gating arm is retained despite awakening clustering being a minority presentation: morning predominance carries prognostic weight even where it is not the typical pattern.

Recruitment of Motor Systems into Tonic-Clonic Output

When hypersynchronous activity crosses the threshold at which it recruits motor cortex and brainstem tonic and clonic generators, the clinical output is a generalized tonic-clonic seizure rather than the behavioral arrest of an absence or the brief jerk of a myoclonic seizure. Why the same class of network abnormality produces convulsive output alone in this syndrome, and absence or myoclonus in its siblings, is not established; it is curated here as a difference in network engagement rather than a distinct etiology, and the uncertainty is recorded as an explicit knowledge gap.

Chemical Synaptic Transmission GO:0007268 ⚠ ABNORMAL

Downstream

Recurrent Unprovoked Generalized Tonic-Clonic Seizures

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"The goal of this paper is to delineate the four syndromes comprising the IGEs, namely childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone."

Establishes EGTCA as a distinct ILAE syndrome whose seizure output differs from its siblings despite a shared mechanism class. Evidence source is OTHER because this is an expert-consensus position statement rather than a primary study.

Recurrent Unprovoked Generalized Tonic-Clonic Seizures

The established clinical disease: recurrent unprovoked generalized tonic-clonic seizures with no other seizure type, normal cognition, and normal imaging. Seizures are typically infrequent, respond well to antiseizure medication, and carry the injury risk inherent to convulsive seizures rather than the cognitive burden of the encephalopathic epilepsies.

Downstream

Seizure-Related Injury

Show evidence (1 reference)

PMID:38819591 SUPPORT Human Clinical

"A GTC recurred in 14% of patients treated with ASM compared with 73% of untreated patients (p < 0.00001)."

Establishes that untreated EGTCA is a recurrent seizure disorder in the large majority of patients, and that treatment substantially changes that, in a prospective cohort diagnosed by explicit ILAE criteria.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Nervous System 3

Generalized Tonic-Clonic Seizures OBLIGATE Bilateral tonic-clonic seizure HP:0002069

Onset: JUVENILE; mean 16.6y (range 5.4-38.3y)

Show evidence (3 references)

PMID:35503716 SUPPORT Other

"juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone"

The syndrome name itself asserts generalized tonic-clonic seizures as the sole seizure type, which is the basis for the OBLIGATE frequency. Evidence source is OTHER because this is a consensus position statement.

PMID:38819591 SUPPORT Human Clinical

"The mean age at seizure onset was 16.6 years (median 16.0 years; range: 5.4-38.3 years)."

The age-at-onset statistic itself, in a cohort assembled against mandatory ILAE criteria, and the source of the mean/min/max values on the onset descriptor. An earlier draft quoted the cohort's median age at inclusion instead, which is a different quantity.

PMID:37872695 SUPPORT Human Clinical

"age at onset of 17 years"

Independent replication of second-decade onset in the largest ILAE-2022-criteria EGTCA cohort, at n = 247.

Seizures Confined to the Two Hours After Awakening FREQUENT Bilateral tonic-clonic seizure HP:0002069

Temporal: RECURRENT

Frequency band note. FREQUENT rests on the 30% figure, which sits barely inside the 30-79% band, and on a single cohort. An earlier draft of this entry justified the band with the cohort's 59.6% "exclusively diurnal" statistic; that was wrong, because diurnal is a much weaker claim than within-two-hours-of-awakening, and it is corrected here.

Show evidence (3 references)

PMID:38819591 SUPPORT Human Clinical

"In our study, only 30% of patients exclusively experienced seizures within 2 h upon waking, a finding that challenges the conventional view which posits that most seizures in this syndrome will occur shortly after awakening."

The directly relevant statistic and the authors' own caveat against over-reading it. 30% is the basis for FREQUENT, and the same sentence is why this entry does not describe awakening clustering as the syndrome's defining feature.

PMID:38819591 SUPPORT Human Clinical

"Our results indicate that seizures could manifest at any time of the day or night, with a tendency toward a mixed circadian pattern in 28% of patients."

Bounds the phenotype in the other direction by documenting that seizures are not time-restricted in this syndrome and that a mixed pattern is common.

PMID:10996562 SUPPORT INDIRECT Human Clinical

"generalized tonic clonic seizures (GTCS) occurring predominantly on awakening (independent of the time of day) or at leisure time (almost at evening)"

The classical description of awakening-linked timing, and the source of the syndrome's historical name. Graded INDIRECT because it describes the pre-2022 "awakening epilepsy" entity, which required awakening predominance by definition, so it cannot establish the frequency of that pattern within the broader ILAE-2022 syndrome.

Absence Seizures Absent EXCLUDED Generalized non-motor (absence) seizure HP:0002121

∅ ABSENT

This descriptor and the myoclonic one below use `modifier: ABSENT` on the excluded seizure type rather than reusing the syndrome's own seizure term. An earlier draft bound both exclusions to HP:0002069, which is semantically backwards: it asserted bilateral tonic-clonic seizure three times over instead of stating what is absent. The two exclusions are also split into separate phenotypes so each carries its own term rather than being bundled. The absence is carried by `frequency: EXCLUDED`, which is what the HPOA exporter reads to emit a NOT-qualified row; `modifier: ABSENT` alone is not consulted by the export layer and documents intent only.

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"Patients that do not fulfill criteria for one of these syndromes, but that have one, or a combination, of the following generalized seizure types: absence, myoclonic, tonic-clonic and myoclonic-tonic-clonic seizures, with 2.5-5.5 Hz generalized spike-wave should be classified as having GGE."

Establishes that seizure-type combination is what partitions this syndrome group, and that patients falling outside the four defined syndromes go to the residual GGE category rather than into EGTCA. Evidence source is OTHER because this is a consensus position statement.

Other 4

Generalized Spike-Wave Discharges VERY_FREQUENT EEG with spike-wave complexes HP:0010850

Show evidence (2 references)

PMID:38819591 SUPPORT Human Clinical

"Generalized spike-wave discharges (GSWD) were present in the initial EEG of 88% of patients."

Directly quantifies generalized spike-wave discharges in an EGTCA cohort. 88% falls in the 80-100% band supporting VERY_FREQUENT.

PMID:35503716 SUPPORT INDIRECT Other

"with 2.5-5.5 Hz generalized spike-wave"

Gives the ILAE frequency band for the generalized spike-wave activity expected across this syndrome group. Graded INDIRECT because the sentence it comes from defines the residual genetic generalized epilepsy category rather than EGTCA specifically, though the same discharge band applies.

Photoparoxysmal EEG Response FREQUENT EEG with photoparoxysmal response HP:0010852

Show evidence (3 references)

PMID:38819591 SUPPORT Human Clinical

"A photoparoxysmal response was elicited on the initial EEG of 18 patients (20.2%) and in 31 patients (34.8%) when all follow-up EEGs are considered."

EGTCA-specific rates under 2022 ILAE criteria. The cumulative 34.8% falls in the 30-79% band and is the basis for FREQUENT; the 20.2% single-EEG figure is why the description separates the two.

PMID:38819591 SUPPORT Human Clinical

"Photosensitivity is common in EGTCA, with reported frequencies ranging from 13% to 62%."

Gives the literature range, which spans the OCCASIONAL and FREQUENT bands and is why this entry cites a cohort figure rather than asserting a precise rate.

PMID:11442158 SUPPORT INDIRECT Human Clinical

"PPR accounted for 17.4% (p < 0.01) of the patients with juvenile myoclonic epilepsy, 7.6% (p < 0.01) of those with grand mal on awakening, and 6.1% (p < 0.01) of those with symptomatic occipital lobe epilepsy."

Useful only for the relative comparison with juvenile myoclonic epilepsy. Graded INDIRECT, and NOT used to set the frequency band, because it counts the pre-2022 "grand mal on awakening" entity rather than EGTCA, and because the same paper notes its cohort's photoparoxysmal rate was low relative to European series.

Normal Interictal Neurological and Cognitive Status VERY_FREQUENT

No ontology term is bound here on purpose. HPO has no positive term for normal interictal status, and binding this to the syndrome's seizure term (as an earlier draft did) would export a false assertion. Omitting `term:` is the established pattern in this repository for a phenotype the ontology cannot express.

Show evidence (2 references)

PMID:38819591 SUPPORT Human Clinical

"Four patients (4.5%) were diagnosed with mild developmental delay and five patients (5.6%) had concomitant psychiatric comorbidity, predominantly depression and/or anxiety disorder."

Quantifies the exception rather than the rule: 4.5% with developmental delay implies roughly 95% with normal development in an EGTCA cohort, which is the basis for the VERY_FREQUENT band. It also shows the claim is about development and cognition, not about freedom from psychiatric comorbidity.

PMID:38165295 SUPPORT INDIRECT Other

"Emerging evidence reveals that patients with IGE may go undiagnosed or misdiagnosed with focal epilepsy if EEG or semiology have asymmetric or focal features."

Supports the diagnostic importance of the expected normal, symmetric, non-focal picture by describing what happens when it is departed from. Graded INDIRECT because it evidences the diagnostic consequence rather than quantifying normal status, and evidence_source is OTHER because this is a review.

Myoclonic Seizures Absent EXCLUDED HP:0032794

∅ ABSENT

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"Patients that do not fulfill criteria for one of these syndromes, but that have one, or a combination, of the following generalized seizure types: absence, myoclonic, tonic-clonic and myoclonic-tonic-clonic seizures, with 2.5-5.5 Hz generalized spike-wave should be classified as having GGE."

Same partitioning rule as for the absence exclusion: myoclonic seizures move a patient out of EGTCA. Evidence source is OTHER because this is a consensus position statement.

🧬

Genetic Associations

1

CLCN2

Gene: CLCN2 hgnc:2020 relationship_type: SUSCEPTIBILITY

Show evidence (3 references)

PMID:19191339 SUPPORT INDIRECT In Vitro

"Functional characterization of mutant channels using heterologous expression in mammalian cells and whole-cell patch-clamp recordings revealed faster deactivation kinetics as the major phenotype of both missense mutations."

Establishes a measured functional consequence for the candidate variants. Graded INDIRECT, and IN_VITRO, because the electrophysiology was done in a heterologous expression system and demonstrates an altered channel property, not a contribution to human EGTCA.

PMID:19191339 SUPPORT Human Clinical

"They may instead represent susceptibility factors among other so far undetected genetic alterations in the respective families."

The authors' own conclusion refutes a causative reading of these variants and supports the SUSCEPTIBILITY typing used here.

PMID:16932951 SUPPORT Human Clinical

"We conclude that mutations in the CLCN2 gene are only a rare cause of idiopathic generalized epilepsy."

An independent screening series that found no definite mutations, bounding how much of the syndrome CLCN2 can explain.

💊

Medical Actions

4

Valproate

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867

Sodium valproate is the reference first-line agent for generalized tonic-clonic seizures in the idiopathic generalized epilepsies and the comparator against which alternatives are judged; it was the initial drug for 68% of patients in the prospective EGTCA cohort. In a randomized non-inferiority trial in newly diagnosed generalized and unclassifiable epilepsy, levetiracetam failed to demonstrate non-inferiority to valproate. Its use is constrained by teratogenicity, so it is avoided in people of childbearing potential where an alternative is viable, and that trade-off is a shared decision rather than an automatic exclusion.

Mechanism Target:

INHIBITS Recurrent Unprovoked Generalized Tonic-Clonic Seizures — Valproate suppresses the clinical seizure output rather than correcting the underlying polygenic susceptibility, which is why relapse is common on withdrawal.

Show evidence (2 references)

PMID:38819591 SUPPORT INDIRECT Human Clinical

"A GTC recurred in 14% of patients treated with ASM compared with 73% of untreated patients (p < 0.00001)."

The best available EGTCA-specific evidence that pharmacotherapy suppresses seizure recurrence, in a cohort where valproate was the initial agent for 68% of patients. Graded INDIRECT because the contrast is treated versus untreated rather than valproate versus another drug, so it cannot isolate valproate's contribution.

PMID:32030724 SUPPORT INDIRECT Human Clinical

"Valproate reduced the risk of experiencing GTCSs significantly (OR: 0.58; 95% CI: 0.34-0.99; P = .04)."

Marked INDIRECT, and deliberately not used as the primary support, because the outcome modeled is whether an IGE patient has generalized tonic-clonic seizures at all. The comparison group is IGE patients without such seizures, mostly absence and myoclonic syndromes, so within EGTCA - where every patient has them by definition - this odds ratio cannot describe a treatment effect. It is retained as class-level context only, and the causal reading in an earlier draft of this explanation was withdrawn.

Show evidence (2 references)

PMID:33838758 SUPPORT Human Clinical

"Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission"

Randomized trial evidence that the leading alternative failed to match valproate, which is the basis for retaining valproate as the reference first-line agent.

PMID:33838758 SUPPORT INDIRECT Human Clinical

"Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity."

States the teratogenicity constraint that governs prescribing. Graded INDIRECT because this is the trial's background framing rather than a teratogenicity result generated by the trial itself.

Levetiracetam

Action: Pharmacotherapy NCIT:C15986

Agent: levetiracetam CHEBI:6437

Levetiracetam is the most commonly used alternative to valproate and is preferred in people of childbearing potential because of its substantially lower teratogenic risk. The honest framing is that this is a trade-off rather than an equivalence: SANAD II found levetiracetam neither non-inferior nor cost-effective against valproate, so the choice buys reproductive safety at some cost in seizure control.

Mechanism Target:

INHIBITS Recurrent Unprovoked Generalized Tonic-Clonic Seizures — Suppression of clinical seizure output, with the same non-disease-modifying caveat as valproate.

Show evidence (1 reference)

PMID:38819591 SUPPORT INDIRECT Human Clinical

"A GTC recurred in 14% of patients treated with ASM compared with 73% of untreated patients (p < 0.00001)."

Demonstrates that antiseizure medication as a class suppresses seizure recurrence in EGTCA specifically. Graded INDIRECT because the comparison is treated versus untreated rather than levetiracetam-specific.

Show evidence (1 reference)

PMID:33838758 SUPPORT INDIRECT Human Clinical

"For girls and women of child-bearing potential, these results inform discussions about benefit and harm of avoiding valproate."

Frames the levetiracetam choice as a benefit-harm discussion rather than a straightforward substitution. Graded INDIRECT because it supports the decision framing rather than establishing levetiracetam efficacy.

Lamotrigine

Action: Pharmacotherapy NCIT:C15986

Agent: lamotrigine CHEBI:6367

Lamotrigine is an alternative broad-spectrum option for generalized tonic-clonic seizures with low teratogenic risk, requiring slow titration because of rash risk and dose adjustment when combined with valproate, which inhibits its metabolism.

Sleep hygiene and precipitant avoidance counseling

Action: Supportive Care NCIT:C15747

Regularizing sleep schedule, avoiding sleep deprivation, and moderating alcohol are the non-pharmacological cornerstone of management, and follow directly from the syndrome's defining sensitivity to sleep-wake state. This is the one intervention that acts on the modulating input rather than on the seizure output.

Mechanism Target:

INHIBITS Sleep-Wake State Gating of Seizure Threshold — Removing the precipitant removes the transient threshold reduction that converts a hyperexcitable network into a clinical seizure.

Show evidence (1 reference)

PMID:10996562 SUPPORT Human Clinical

"The common denominator of external seizures precipitating influences is lack of sleep."

Identifies the modifiable precipitant that this intervention targets. No trial evidence was identified showing that counseling changes seizure outcomes in EGTCA.

🌍

Environmental Factors

2

Sleep deprivation

Sleep deprivation is the most frequently named precipitant among EGTCA patients who can identify one, and the practical target of lifestyle counseling. It should not be over-sold: about half of patients in the prospective cohort could identify no trigger at all. It acts by transiently lowering seizure threshold in an already hyperexcitable network rather than by causing the underlying epilepsy.

Show evidence (2 references)

PMID:38819591 SUPPORT Human Clinical

"Forty-six patients (51.7%) were unable to identify a trigger for their seizures. Among the remaining 43 patients, the most frequent precipitating factors included sleep deprivation reported by 34 patients and severe stress reported by nine."

The EGTCA-specific trigger data, and the basis for both halves of the description: sleep deprivation dominates among identifiable triggers (34 of 43), yet a slight majority of patients identify no trigger at all.

PMID:24632482 SUPPORT INDIRECT Human Clinical

"Of 104 patients, 97% cited at least one precipitant. Stress, sleep deprivation, and fatigue were the most frequently reported precipitants."

Class-level context from a general epilepsy clinic. Marked INDIRECT because the population is all-comers rather than EGTCA, and because its 97% trigger-identification rate is strikingly higher than the EGTCA cohort's 48%, which is a reason to prefer the syndrome-specific figure.

Mechanism Target:

EXACERBATES Sleep-Wake State Gating of Seizure Threshold — Sleep loss is the unifying external precipitant across awakening epilepsy, acting on the sleep-wake state modulation of seizure threshold.

Show evidence (1 reference)

PMID:10996562 SUPPORT Human Clinical

"The common denominator of external seizures precipitating influences is lack of sleep."

Names sleep loss as the common denominator among precipitating influences in this syndrome, which is the exacerbating edge asserted here.

Habitual late and unstable sleep pattern

Beyond acute sleep loss, patients with awakening epilepsy have been characterized as late sleepers and late risers whose habitual schedule predisposes to chronic sleep debt, with polygraphic evidence of less stable sleep. This is a chronic predisposing exposure distinct from an acute precipitant, which is why it is typed PREDISPOSES rather than EXACERBATES.

Show evidence (1 reference)

PMID:10996562 SUPPORT Human Clinical

"The sleep habits of patients with AE who could roughly be characterized as late sleepers and late risers may dispose them to a chronic sleep deficit."

Attributes the chronic sleep debt in this syndrome to habitual sleep timing rather than to any single night of lost sleep, which is what makes the habitual pattern an exposure in its own right.

Mechanism Target:

PREDISPOSES Sleep-Wake State Gating of Seizure Threshold — A habitually late and unstable sleep schedule maintains a chronic sleep deficit that keeps the state-gated seizure threshold persistently lower.

Show evidence (1 reference)

PMID:10996562 SUPPORT Human Clinical

"The sleep habits of patients with AE who could roughly be characterized as late sleepers and late risers may dispose them to a chronic sleep deficit."

Directly asserts the predisposing role of habitual sleep timing, hedged by the source's own "may dispose", which the PREDISPOSES typing preserves.

🔬

Diagnosis

2

Sleep-deprived EEG with serial recording

Generalized spike-wave discharge is mandatory for the diagnosis, so the EEG protocol is not incidental to it. A 3-hour sleep-deprived recording captured discharges in 88% of patients on the first study in the prospective cohort, and repeating the EEG recovered most of the remainder. A single normal routine EEG therefore does not exclude EGTCA, and serial sleep-deprived recordings are the practical standard.

Show evidence (2 references)

PMID:38819591 SUPPORT Human Clinical

"Participants underwent a 3-h sleep-deprived video-EEG recording along with an epilepsy protocol brain magnetic resonance imaging (MRI) with repeat EEG at each follow-up."

Documents the diagnostic protocol under which the cohort's 88% first-EEG yield was obtained, which is what makes that figure actionable rather than abstract.

PMID:38819591 SUPPORT Human Clinical

"The significance of these findings is underscored by the mandatory presence of GSWD for diagnosing EGTCA."

Establishes that the EEG finding is a required diagnostic criterion, not merely supportive, which is why EEG yield matters so much in this syndrome.

MRI to exclude a structural lesion

Brain MRI is performed to exclude a structural cause rather than to confirm EGTCA; the syndrome is non-lesional by definition. Focal slowing or a persistent focal EEG abnormality should prompt reconsideration of the diagnosis rather than reassurance.

Show evidence (1 reference)

PMID:38819591 SUPPORT INDIRECT Human Clinical

"along with an epilepsy protocol brain magnetic resonance imaging (MRI)"

Confirms that dedicated epilepsy-protocol MRI was part of the diagnostic workup in the ILAE-criteria cohort. Graded INDIRECT because it documents that imaging was performed rather than reporting the yield, so it supports the practice without quantifying how often a lesion is found.

📈

Progression

3

Early treatment response

Age: Adolescence to young adulthood

EGTCA is among the more manageable idiopathic generalized epilepsies. Most patients respond promptly to antiseizure medication and drug resistance is uncommon at 16.3% in the largest cohort, but a substantial minority follow a relapsing-remitting course rather than a clean remission, so the syndrome should not be described as uniformly benign.

Show evidence (4 references)

PMID:37872695 SUPPORT Human Clinical

"Drug resistance at the last visit was observed in 40 (16.3%) patients"

Puts a number on the "drug resistance is uncommon" claim rather than leaving it qualitative.

PMID:37872695 SUPPORT Human Clinical

"had no-remission and relapsing-remitting patterns, respectively."

Anchors the relapsing-remitting subgroup, which in that cohort was 36.3% of patients followed at least five years, against 8% with no remission.

PMID:37872695 SUPPORT Human Clinical

"GTCA could be considered a relatively easily manageable IGE syndrome, with a low rate of drug resistance and a high prevalence of early response to treatment."

Multicenter confirmation of the favorable treatment-response profile in a cohort defined by the 2022 ILAE criteria.

+ 1 more reference

Attempted medication withdrawal

Age: Young adulthood onward

Lifelong treatment is not always necessary, but relapse after withdrawal is frequent, and the two ILAE-criteria cohorts disagree sharply on how frequent: 44% recurrence in the prospective cohort versus 83% in the larger retrospective one. That gap is not resolved here and should not be averaged away; it plausibly reflects differences in follow-up duration, in who was selected for a withdrawal attempt, and in how recurrence was ascertained. The predictors also differ by cohort. The prospective cohort found patient-initiated tapering and a mixed diurnal-nocturnal seizure pattern independently predicted recurrence, and reported success where seizure freedom was long-standing and generalized spike-wave had resolved; the retrospective cohort found longer seizure freedom to be the only predictor of successful withdrawal. The circadian predictor links prognosis back to the sleep-wake gating node in the pathophysiology.

Show evidence (4 references)

PMID:38819591 SUPPORT Human Clinical

"ASM discontinuation was attempted in 50 patients after a median treatment duration of 3 years, with 44% experiencing a recurrence."

Quantifies relapse risk on withdrawal in an EGTCA-specific prospective cohort.

PMID:38819591 SUPPORT Human Clinical

"Patient-initiated taper and a mixed circadian seizure pattern independently predicted a higher likelihood of recurrence post-ASM discontinuation."

Identifies the two independent predictors of relapse, including the circadian pattern that ties prognosis to the sleep-wake gating node.

PMID:37872695 SUPPORT Human Clinical

"At the last visit, 49 (83%) of those patients had experienced GTCS recurrence."

The competing relapse estimate. Curated alongside the 44% figure rather than in place of it, because the two ILAE-criteria cohorts genuinely disagree and picking one would misrepresent the state of the evidence.

+ 1 more reference

Long-term outcome

Age: Adulthood to late adulthood

Over decades of follow-up, long-term seizure outcome in EGTCA is very similar to that of the other adolescent-onset generalized genetic epilepsies, with most patients reaching terminal remission. Age at first seizure is the feature that most clearly separates EGTCA from juvenile absence and juvenile myoclonic epilepsy, being several years later.

Show evidence (2 references)

PMID:28464258 SUPPORT Human Clinical

"Age at first seizure was significantly higher in EGTCS patients (median 18 years) than in patients with JAE or JME (14 years each; p ≤ 0.001)."

Establishes the later onset of EGTCA relative to its sibling syndromes in a cohort with a median 42.5-year follow-up.

PMID:28464258 SUPPORT Human Clinical

"Long-term outcome was shown to be highly similar across all subsyndromes of adolescent-onset GGE."

Supports curating long-term prognosis at the adolescent-onset GGE level rather than asserting an EGTCA-specific long-term trajectory.

📊

Prevalence

2

Patients diagnosed with an idiopathic generalized epilepsy

Unknown Unknown

Recorded as a share of idiopathic generalized epilepsy diagnoses rather than as a population rate. Reported proportions vary widely across cohorts and diagnostic eras, so no population rate is asserted here; the 31% figure is from a single prospective center applying mandatory ILAE criteria and should not be read as a general population estimate. measure_type is UNKNOWN rather than POINT_PREVALENCE on purpose: this is a share of a diagnostic group, and PrevalenceMeasureEnum has no value for that, so claiming a point prevalence would misdescribe the statistic.

Show evidence (1 reference)

PMID:38819591 SUPPORT Human Clinical

"Eighty-nine patients with a median age of 16 years were included, constituting 31% of those diagnosed with an idiopathic generalized epilepsy."

Gives the syndrome's share of idiopathic generalized epilepsy diagnoses in a prospective multicenter cohort using mandatory ILAE criteria.

All epilepsies

Unknown Unknown

Class-level context only. The idiopathic generalized epilepsies as a group account for roughly a fifth of all epilepsies; EGTCA is one of four syndromes within that fifth, and no reliable syndrome-level population rate was identified during curation. As above, measure_type is UNKNOWN because this records a share of all epilepsies, not a population rate for EGTCA.

Show evidence (1 reference)

PMID:38165295 SUPPORT INDIRECT Other

"The idiopathic generalized epilepsies (IGE) make up a fifth of all epilepsies, but <1% of epilepsy research."

Establishes the class-level share of all epilepsies. Marked INDIRECT because it covers the four-syndrome group rather than EGTCA alone, and evidence_source is OTHER because this is a review.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Epilepsy with Generalized Tonic-Clonic Seizures Alone:

Focal epilepsy with focal to bilateral tonic-clonic seizures

Overlapping Features The most consequential differential, because the two are treated differently. Focal epilepsy is distinguished by focal EEG onset, aura or focal semiology, and a structural lesion when one is present. The error runs in both directions: idiopathic generalized epilepsy is itself misdiagnosed as focal epilepsy when EEG or semiology carry asymmetric or focal features.

Show evidence (1 reference)

PMID:38165295 SUPPORT Other

"Emerging evidence reveals that patients with IGE may go undiagnosed or misdiagnosed with focal epilepsy if EEG or semiology have asymmetric or focal features."

Documents the misdiagnosis risk in the generalized-to-focal direction, which is the less commonly taught half of this differential. Evidence source is OTHER because this is a review.

Juvenile myoclonic epilepsy and juvenile absence epilepsy

Overlapping Features The sibling idiopathic generalized epilepsy syndromes, separated from EGTCA solely by the presence of myoclonic jerks or absence seizures. Because myoclonus may be underreported unless specifically asked about, the distinction depends on the quality of the history as much as on the EEG.

Show evidence (1 reference)

PMID:35503716 SUPPORT Other

"The goal of this paper is to delineate the four syndromes comprising the IGEs, namely childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic seizures alone."

Establishes the four syndromes as separate entities requiring differentiation from one another. Evidence source is OTHER because this is a consensus position statement.

Drug-resistant generalized epilepsy outside the IGE definition

Overlapping Features A meaningful proportion of patients who meet the 2022 IGE criteria on paper have refractory seizures or atypical features, and whether these lie inside the syndrome's spectrum or represent a distinct entity is unsettled. This matters for EGTCA because drug resistance is otherwise uncommon here, so a refractory course should prompt reconsideration rather than escalation alone.

Show evidence (1 reference)

PMID:38508955 SUPPORT Other

"Indeed, among patients presenting with a syndrome compatible with the 2022 definition of IGEs, we still observe a significant proportion of patients presenting with specific clinical features, refractory seizures, or drug-resistant epilepsies."

Documents the boundary problem directly. Evidence source is OTHER because this is a review article.

{ }

Source YAML

click to show

name: Epilepsy with Generalized Tonic-Clonic Seizures Alone
creation_date: "2026-08-09T00:00:00Z"
category: Complex
description: >-
  Epilepsy with generalized tonic-clonic seizures alone (EGTCA) is the fourth of
  the four idiopathic generalized epilepsy syndromes recognized by the ILAE,
  alongside childhood absence epilepsy, juvenile absence epilepsy, and juvenile
  myoclonic epilepsy. It is defined negatively as much as positively: generalized
  tonic-clonic seizures are the sole seizure type, and the presence of absence or
  myoclonic seizures moves the diagnosis to one of the sibling syndromes. Onset is
  typically in the second decade. The syndrome was historically called awakening
  epilepsy or grand mal on awakening because seizures were thought to cluster
  shortly after waking, but the contemporary ILAE-criteria cohorts do not support
  that as a majority feature: only about 30% of patients have seizures confined to
  the two hours after awakening, and roughly a quarter have a mixed
  diurnal-nocturnal pattern. Sleep deprivation remains the most frequently
  identified precipitant among patients who can name one, though about half cannot.
  The EEG background is normal and carries generalized spike-wave discharges;
  neuroimaging shows no lesion. The mechanism is a heritable, polygenic
  cortico-thalamocortical hyperexcitability whose seizure output is modulated,
  though not reliably dominated, by sleep-wake state.
parents:
  - Epilepsy
  - Neurological Disease
synonyms:
  - EGTCA
  - EGTCSA
  - epilepsy with generalized tonic-clonic seizures alone
  - epilepsy with grand mal on awakening
  - awakening epilepsy
  - Aufwach-Epilepsie
disease_term:
  preferred_term: epilepsy with generalized tonic-clonic seizures alone
  term:
    id: MONDO:0005754
    label: epilepsy with generalized tonic-clonic seizures
mappings:
  mondo_mappings:
    - term:
        id: MONDO:0005754
        label: epilepsy with generalized tonic-clonic seizures
      mapping_predicate: skos:exactMatch
      mapping_source: MONDO
      mapping_justification: >-
        MONDO:0005754 carries "epilepsy with generalized tonic-clonic seizures
        alone" and "EGTCA" as EXACT synonyms and cross-references Orphanet:698005,
        the Orphanet concept for this ILAE syndrome. The MONDO label is the
        shorter form, so the entry name and the term label deliberately differ.
references:
  - reference: PMID:35503716
    title: >-
      ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position
      statement by the ILAE Task Force on Nosology and Definitions.
  - reference: PMID:38819591
    title: >-
      Prospective study of epilepsy with generalized tonic-clonic seizures alone:
      Clinical features, response to treatment, and likelihood of medication
      withdrawal.
  - reference: PMID:37872695
    title: >-
      Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
      features and prognostic patterns.
notes: >-
  Scope note. This entry completes the ILAE idiopathic generalized epilepsy
  tetrad in the knowledge base, joining the existing Childhood_Absence_Epilepsy,
  Juvenile_Absence_Epilepsy, and Juvenile_Myoclonic_Epilepsy entries. EGTCA is
  defined partly by exclusion, so the entry deliberately curates the *absence* of
  absence and myoclonic seizures as a diagnostic boundary rather than silently
  omitting them.

  Evidence-level note. Most genomic and network-physiology evidence in the
  literature is at the level of the idiopathic/genetic generalized epilepsy class
  rather than EGTCA specifically. Where a claim rests on class-level rather than
  syndrome-level data, the evidence item carries directness: INDIRECT and the
  explanation says so. The one place this is unusually well documented is the GWAS: the 2023
  ILAE meta-analysis stratified by IGE subtype and found no genome-wide
  significant locus for EGTCA, which is curated here as a positive statement
  about sample size and polygenicity rather than quietly generalized from the
  pooled result.

  Module conformance note. Five nodes declare conformance to
  epilepsy_excitation_inhibition_imbalance. The EGTCA graph adds a state-gating
  arm the generic module does not carry: sleep-wake transition physiology acts as
  a modulator on the hyperexcitable network rather than as a step in the causal
  chain from channel lesion to seizure. That arm is modeled as its own node with
  an edge into seizure generation because state gating is prognostically load
  bearing here - a mixed circadian pattern predicts relapse after medication
  withdrawal, and morning predominance predicts drug resistance - not because
  awakening-clustered seizures are the majority presentation. See the naming
  caveat below.

  Naming caveat. The historical names awakening epilepsy, grand mal on awakening,
  and Aufwach-Epilepsie are retained as synonyms because the literature is indexed
  under them, but they are NOT interchangeable with the 2022 ILAE syndrome. The
  1989 entity required awakening predominance; EGTCA does not, and the prospective
  ILAE-criteria cohort explicitly reports that its data challenge the conventional
  awakening view. Curators should not treat a pre-2022 "grand mal on awakening"
  cohort as an EGTCA-specific source without saying so. This entry marks one such
  borrowed statistic with the pre-2022 cohort named for exactly that reason, and
  the same conflation is what polluted the dataset search described below.

  Dataset note. This entry deliberately carries no `datasets:` block. Dataset
  discovery was run and returned twelve candidates, none of which survived
  relevance triage: the CLCN2-keyed hits are about corn snake skin pigmentation,
  familial hyperaldosteronism, leukodystrophy, and retinal degeneration, because
  CLCN2 is famous for diseases other than this one; the name-keyed hits are
  audiogenic-seizure rodent strains, an HCN1 mouse developmental and epileptic
  encephalopathy, a temporal lobe epilepsy model, and, via the historical synonym
  "grand mal epilepsy", an autism blood-expression study. Every one of those
  accessions resolves perfectly and would have passed the automated verifier, so
  the exclusion is a curatorial judgement rather than a tooling result. No omics
  dataset specific to EGTCA was identified.

  Drug-aggravation caveat. The blanket "avoid sodium channel blockers in IGE"
  teaching is weaker for EGTCA than for its sibling syndromes, and the entry says
  so rather than repeating the generalization. The primary aggravation evidence
  concerns myoclonic and absence seizures, which EGTCA patients do not have by
  definition; in the oxcarbazepine series the effect on generalized tonic-clonic
  seizures was explicitly described as less dramatic. This is recorded as an open
  discussion rather than resolved in either direction.
inheritance:
  - name: Polygenic susceptibility
    description: >-
      EGTCA is heritable but not Mendelian. Liability is distributed across many
      common variants of small effect together with rarer variants in ion channel
      and neurotransmitter receptor genes shared across the idiopathic generalized
      epilepsies. Relatives of an EGTCA proband who are affected typically have
      some other generalized epilepsy phenotype rather than EGTCA itself, which is
      the expected behavior of a shared polygenic liability rather than
      syndrome-specific transmission. Routine single-gene testing is
      correspondingly not part of clinical evaluation.
    inheritance_term:
      preferred_term: Polygenic inheritance
      term:
        id: HP:0010982
        label: Polygenic inheritance
    evidence:
      - reference: PMID:37653029
        reference_title: >-
          GWAS meta-analysis of over 29,000 people with epilepsy identifies 26
          risk loci and subtype-specific genetic architecture.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          suggesting that the signals are primarily driven by polygenicity
        explanation: >-
          The consortium's own reading of its linkage-disequilibrium score
          regression intercepts is that the generalized epilepsy association
          signal is polygenic rather than driven by a few large-effect loci, which
          is the architecture this inheritance block asserts.
      - reference: PMID:19191339
        reference_title: >-
          Two novel CLCN2 mutations accelerating chloride channel deactivation are
          associated with idiopathic generalized epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          However, the incomplete segregation of the mutations among affected
          members and the transmission by unaffected parents suggests that these
          CLCN2 mutations alone are not sufficient to induce epilepsy.
        explanation: >-
          A worked demonstration of non-Mendelian behavior in the leading
          candidate gene: variants that do not segregate with disease and are
          transmitted by unaffected parents are susceptibility factors, not
          causative alleles.
pathophysiology:
  - name: Polygenic Susceptibility to Generalized Epilepsy
    biological_scale: MOLECULAR
    role: trigger
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
    description: >-
      Susceptibility is conferred by many common variants of individually small
      effect together with rarer variants in genes encoding neuronal ion channels
      and neurotransmitter receptors, in particular voltage-gated calcium and
      chloride channels and GABA-A receptor subunits. No single gene is necessary
      or sufficient. The net effect is a lowered seizure threshold in
      cortico-thalamocortical circuits rather than a discrete molecular lesion,
      which is why the node is a distributed liability rather than a named
      mutation.
    cell_types:
      - preferred_term: Neuron
        term:
          id: CL:0000540
          label: neuron
    biological_processes:
      - preferred_term: Regulation of Membrane Potential
        term:
          id: GO:0042391
          label: regulation of membrane potential
        modifier: ABNORMAL
      - preferred_term: Chemical Synaptic Transmission
        term:
          id: GO:0007268
          label: chemical synaptic transmission
        modifier: ABNORMAL
    downstream:
      - target: Cortico-Thalamocortical Excitation-Inhibition Imbalance
    evidence:
      - reference: PMID:37653029
        reference_title: >-
          GWAS meta-analysis of over 29,000 people with epilepsy identifies 26
          risk loci and subtype-specific genetic architecture.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Our 'GGE' meta-analysis uncovered a total of 25 independent genome-wide
          significant signals across 22 loci, of which 13 loci are new.
        explanation: >-
          Establishes a many-loci common-variant architecture for genetic
          generalized epilepsy, the class to which EGTCA belongs, which is the
          distributed liability this node models.
      - reference: PMID:37653029
        reference_title: >-
          GWAS meta-analysis of over 29,000 people with epilepsy identifies 26
          risk loci and subtype-specific genetic architecture.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We did not find any genome-wide significant loci for JAE (n = 671),
          GTCSA (n = 499)
        explanation: >-
          The syndrome-stratified analysis found no EGTCA-specific locus at the
          available sample size. This is an absence of evidence at n = 499 rather than
          evidence that no such locus exists; it supports the polygenic framing while
          bounding how confidently any particular gene can be attached to this syndrome.
  - name: Cortico-Thalamocortical Excitation-Inhibition Imbalance
    biological_scale: CELLULAR
    role: amplifier
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
    description: >-
      The susceptibility alleles shift the balance between glutamatergic
      excitation and GABAergic inhibition within reciprocally connected cortical
      and thalamic populations toward net excitation. The thalamic reticular
      nucleus, whose GABAergic output paces thalamocortical relay neurons, is the
      inhibitory element whose dysfunction is most consistently implicated across
      the idiopathic generalized epilepsies.
    cell_types:
      - preferred_term: GABAergic Neuron
        term:
          id: CL:0000617
          label: GABAergic neuron
      - preferred_term: Thalamic Relay Neuron
        term:
          id: CL:4023068
          label: thalamic excitatory neuron
    biological_processes:
      - preferred_term: GABA Signaling Pathway
        term:
          id: GO:0007214
          label: gamma-aminobutyric acid signaling pathway
        modifier: DECREASED
    locations:
      - preferred_term: Thalamic Reticular Nucleus
        term:
          id: UBERON:0001903
          label: thalamic reticular nucleus
      - preferred_term: Cerebral Cortex
        term:
          id: UBERON:0000956
          label: cerebral cortex
    downstream:
      - target: Generalized Hypersynchronous Discharge
    evidence:
      - reference: PMID:28752060
        reference_title: >-
          Sleep onset uncovers thalamic abnormalities in patients with idiopathic
          generalised epilepsy.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          As interactions between thalamic sub-regions are indirect and mediated
          by the inhibitory thalamic reticular nucleus (TRN), the results suggest
          abnormal TRN function in patients with IGE
        explanation: >-
          Human EEG-fMRI evidence implicating the inhibitory thalamic reticular nucleus
          in idiopathic generalized epilepsy. Graded INDIRECT because the cohort is
          IGE-wide rather than EGTCA-specific, and because the TRN inference is
          indirect, drawn from intra-thalamic connectivity rather than measured
          directly.
      - reference: PMID:38165295
        reference_title: >-
          Idiopathic Generalized Epilepsy: Misunderstandings, Challenges, and
          Opportunities.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: OTHER
        snippet: >-
          Genetic, electrophysiologic, and neuroimaging studies provide insights
          into pathophysiology, including overlaps and differences from focal
          epilepsies.
        explanation: >-
          Supports a network-level rather than lesional pathophysiology for the IGE
          class. Graded INDIRECT, and evidence_source OTHER, because this is a review
          synthesizing across syndromes rather than primary EGTCA data.
  - name: Generalized Hypersynchronous Discharge
    biological_scale: TISSUE
    role: intermediate
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
    description: >-
      Net excitatory bias permits large populations of cortical and thalamic
      neurons to fire in phase, producing the bilaterally synchronous generalized
      spike-wave and polyspike-wave discharges that are the electrographic
      signature of the syndrome. Between discharges the background is normal,
      which is what separates this from the encephalopathic generalized
      epilepsies.
    cell_types:
      - preferred_term: Cortical Pyramidal Neuron
        term:
          id: CL:0000598
          label: pyramidal neuron
      - preferred_term: Corticothalamic Projection Neuron
        term:
          id: CL:4023013
          label: corticothalamic-projecting glutamatergic cortical neuron
    biological_processes:
      - preferred_term: Regulation of Membrane Potential
        term:
          id: GO:0042391
          label: regulation of membrane potential
        modifier: ABNORMAL
    downstream:
      - target: Recruitment of Motor Systems into Tonic-Clonic Output
    evidence:
      - reference: PMID:21269293
        reference_title: Functional connectivity in patients with idiopathic generalized epilepsy.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Although GSWDs are the result of highly synchronized activity in the
          thalamocortical network, EEG without GSWDs is believed to represent
          normal brain activity.
        explanation: >-
          States both halves of this node's claim: the discharges reflect highly
          synchronized thalamocortical activity, and the network is otherwise normal
          between them. Graded INDIRECT because the study population is IGE-wide rather
          than EGTCA-specific.
      - reference: PMID:21269293
        reference_title: Functional connectivity in patients with idiopathic generalized epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The results underscore the paroxysmal nature of GSWDs: Although GSWDs
          are characterized by highly synchronized activity in the thalamocortical
          network, the functional connectivity in areas involved during GSWDs does
          not demonstrate abnormality in GSWD-free periods.
        explanation: >-
          Supports modeling the hypersynchrony as a paroxysmal event on an
          otherwise normal network rather than a continuously abnormal state,
          which is why this node sits downstream of a susceptibility node rather
          than describing a persistent lesion.
  - name: Sleep-Wake State Gating of Seizure Threshold
    biological_scale: ORGANISM
    role: modulator
    description: >-
      The distinctive feature of EGTCA is not that seizures occur but when. The
      transition out of sleep, and sleep deprivation preceding it, transiently
      lower the threshold at which the hyperexcitable network converts into a
      clinical seizure, concentrating seizures in the hour or two after awakening
      independent of clock time. This node is deliberately modeled as a modulator
      acting on seizure generation rather than as a step in the causal chain,
      because it changes the probability and timing of the output without being
      required to produce it.
    biological_processes:
      - preferred_term: Circadian Sleep/Wake Cycle
        term:
          id: GO:0042745
          label: circadian sleep/wake cycle
    downstream:
      - target: Recruitment of Motor Systems into Tonic-Clonic Output
    evidence:
      - reference: PMID:10996562
        reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Awakening epilepsy (AE) is an age related syndrome of idiopathic
          generalized epilepsy (IGE) characterized by generalized tonic clonic
          seizures (GTCS) occurring predominantly on awakening (independent of the
          time of day) or at leisure time (almost at evening).
        explanation: >-
          The defining description of the awakening-linked seizure timing by the
          clinician who delineated the syndrome, and the basis for treating
          sleep-wake state as a distinct modulating input.
      - reference: PMID:10996562
        reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The common denominator of external seizures precipitating influences is
          lack of sleep.
        explanation: >-
          Identifies sleep deprivation as the unifying precipitant, which is the
          threshold-lowering mechanism this node asserts.
      - reference: PMID:24632482
        reference_title: Seizure precipitants (triggering factors) in patients with epilepsy.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Patients with idiopathic generalized epilepsy seemed to be more
          sensitive to seizures during awakening and sleep deprivation
        explanation: >-
          Independent clinic-cohort confirmation that awakening and sleep deprivation
          are differentially potent precipitants in idiopathic generalized epilepsy.
          Graded INDIRECT because the comparison is across broad epilepsy categories
          rather than within EGTCA, and the authors themselves hedge with "seemed to
          be".
  - name: Catamenial Gating of Seizure Threshold
    biological_scale: ORGANISM
    role: modulator
    description: >-
      A second state-gating input, parallel to the sleep-wake one. In some
      patients seizures cluster with the menstrual cycle, and catamenial seizures
      are one of only two features that independently predicted drug resistance in
      the largest ILAE-criteria cohort. It is modeled as a modulator on seizure
      generation for the same reason as the sleep-wake node: it changes when and
      how readily the hyperexcitable network converts to a clinical seizure
      without being required to produce one.
    downstream:
      - target: Recruitment of Motor Systems into Tonic-Clonic Output
    evidence:
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Catamenial seizures and morning predominance of generalized tonic-clonic
          seizures (GTCS) independently predicted drug resistance at the last
          visit according to multivariable logistic regression.
        explanation: >-
          Establishes catamenial seizures as an independent prognostic factor in
          EGTCA, which is what justifies modeling menstrual-cycle gating as its
          own node. The same sentence is the main reason the sleep-wake gating arm
          is retained despite awakening clustering being a minority presentation:
          morning predominance carries prognostic weight even where it is not the
          typical pattern.
    notes: >-
      No hormonal mechanism is asserted here. The evidence is an epidemiological
      association between catamenial seizures and drug resistance; the
      neuroendocrine route from cycle phase to seizure threshold is not curated
      because no EGTCA-specific mechanistic source was identified.
  - name: Recruitment of Motor Systems into Tonic-Clonic Output
    biological_scale: ORGANISM
    role: consequence
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Seizure Generation and Epileptogenesis"
    description: >-
      When hypersynchronous activity crosses the threshold at which it recruits
      motor cortex and brainstem tonic and clonic generators, the clinical output
      is a generalized tonic-clonic seizure rather than the behavioral arrest of
      an absence or the brief jerk of a myoclonic seizure. Why the same class of
      network abnormality produces convulsive output alone in this syndrome, and
      absence or myoclonus in its siblings, is not established; it is curated here
      as a difference in network engagement rather than a distinct etiology, and
      the uncertainty is recorded as an explicit knowledge gap.
    biological_processes:
      - preferred_term: Chemical Synaptic Transmission
        term:
          id: GO:0007268
          label: chemical synaptic transmission
        modifier: ABNORMAL
    downstream:
      - target: Recurrent Unprovoked Generalized Tonic-Clonic Seizures
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The goal of this paper is to delineate the four syndromes comprising the
          IGEs, namely childhood absence epilepsy, juvenile absence epilepsy,
          juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic
          seizures alone.
        explanation: >-
          Establishes EGTCA as a distinct ILAE syndrome whose seizure output
          differs from its siblings despite a shared mechanism class. Evidence
          source is OTHER because this is an expert-consensus position statement
          rather than a primary study.
  - name: Recurrent Unprovoked Generalized Tonic-Clonic Seizures
    biological_scale: ORGANISM
    role: outcome
    conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
    description: >-
      The established clinical disease: recurrent unprovoked generalized
      tonic-clonic seizures with no other seizure type, normal cognition, and
      normal imaging. Seizures are typically infrequent, respond well to
      antiseizure medication, and carry the injury risk inherent to convulsive
      seizures rather than the cognitive burden of the encephalopathic
      epilepsies.
    downstream:
      - target: Seizure-Related Injury
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          A GTC recurred in 14% of patients treated with ASM compared with 73% of
          untreated patients (p < 0.00001).
        explanation: >-
          Establishes that untreated EGTCA is a recurrent seizure disorder in the
          large majority of patients, and that treatment substantially changes
          that, in a prospective cohort diagnosed by explicit ILAE criteria.
  - name: Seizure-Related Injury
    biological_scale: ORGANISM
    role: consequence
    description: >-
      Because every seizure in this syndrome is convulsive by definition, the
      morbidity is dominated by physical injury sustained during the seizure
      rather than by interictal cognitive impairment. This is the mechanistic
      reason the syndrome is not benign despite low seizure frequency and good
      treatment response.
    evidence:
      - reference: PMID:32030724
        reference_title: >-
          Tonic-clonic seizures in idiopathic generalized epilepsies: Prevalence,
          risk factors, and outcome.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Generalized tonic-clonic seizures were significantly associated with
          experiencing seizure-related injuries.
        explanation: >-
          Directly links the convulsive seizure type, which is the only seizure
          type in EGTCA, to injury risk within an idiopathic generalized epilepsy
          cohort.
phenotypes:
  - category: Neurological
    name: Generalized Tonic-Clonic Seizures
    frequency: OBLIGATE
    description: >-
      Generalized tonic-clonic seizures are the defining and, by diagnostic
      definition, the only seizure type. Onset is typically in the second decade,
      with a median age at onset of 16 to 18 years across cohorts. Seizures are
      usually infrequent compared with the daily absences of childhood absence
      epilepsy or the frequent myoclonus of juvenile myoclonic epilepsy.
    phenotype_term:
      preferred_term: Bilateral tonic-clonic seizure
      term:
        id: HP:0002069
        label: Bilateral tonic-clonic seizure
      onset:
        onset_category: JUVENILE
        mean_age_years: 16.6
        min_age_years: 5.4
        max_age_years: 38.3
        notes: >-
          Mean age at seizure onset 16.6 years (median 16.0, range 5.4-38.3) in
          the prospective ILAE-criteria cohort; median 17 years in the larger
          multicenter cohort and 18 years in a long-follow-up adolescent-onset
          series. Onset is characteristically in the second decade but the range
          extends well into adulthood.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic
          seizures alone
        explanation: >-
          The syndrome name itself asserts generalized tonic-clonic seizures as
          the sole seizure type, which is the basis for the OBLIGATE frequency.
          Evidence source is OTHER because this is a consensus position statement.
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The mean age at seizure onset was 16.6 years (median 16.0 years; range:
          5.4-38.3 years).
        explanation: >-
          The age-at-onset statistic itself, in a cohort assembled against
          mandatory ILAE criteria, and the source of the mean/min/max values on
          the onset descriptor. An earlier draft quoted the cohort's median age
          at inclusion instead, which is a different quantity.
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          age at onset of 17 years
        explanation: >-
          Independent replication of second-decade onset in the largest
          ILAE-2022-criteria EGTCA cohort, at n = 247.
  - category: Neurological
    name: Seizures Confined to the Two Hours After Awakening
    frequency: FREQUENT
    description: >-
      Roughly 30% of patients have seizures exclusively within two hours of
      awakening. This is the feature the syndrome was historically named for, but
      the prospective ILAE-criteria cohort states plainly that its own data
      challenge the conventional view that most seizures in this syndrome occur
      shortly after waking. Seizures can occur at any time of day or night, and
      about 28% of patients have a mixed diurnal-nocturnal pattern. The awakening
      pattern is therefore curated as a common but minority presentation, not as
      the defining clinical signature, and its real weight in this entry is
      prognostic rather than diagnostic.
    phenotype_term:
      preferred_term: Bilateral tonic-clonic seizure
      term:
        id: HP:0002069
        label: Bilateral tonic-clonic seizure
      temporality: RECURRENT
    notes: >-
      Frequency band note. FREQUENT rests on the 30% figure, which sits barely
      inside the 30-79% band, and on a single cohort. An earlier draft of this
      entry justified the band with the cohort's 59.6% "exclusively diurnal"
      statistic; that was wrong, because diurnal is a much weaker claim than
      within-two-hours-of-awakening, and it is corrected here.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          In our study, only 30% of patients exclusively experienced seizures
          within 2 h upon waking, a finding that challenges the conventional view
          which posits that most seizures in this syndrome will occur shortly
          after awakening.
        explanation: >-
          The directly relevant statistic and the authors' own caveat against
          over-reading it. 30% is the basis for FREQUENT, and the same sentence is
          why this entry does not describe awakening clustering as the syndrome's
          defining feature.
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Our results indicate that seizures could manifest at any time of the day
          or night, with a tendency toward a mixed circadian pattern in 28% of
          patients.
        explanation: >-
          Bounds the phenotype in the other direction by documenting that seizures
          are not time-restricted in this syndrome and that a mixed pattern is
          common.
      - reference: PMID:10996562
        reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          generalized tonic clonic seizures (GTCS) occurring predominantly on
          awakening (independent of the time of day) or at leisure time (almost at
          evening)
        explanation: >-
          The classical description of awakening-linked timing, and the source of the
          syndrome's historical name. Graded INDIRECT because it describes the pre-2022
          "awakening epilepsy" entity, which required awakening predominance by
          definition, so it cannot establish the frequency of that pattern within the
          broader ILAE-2022 syndrome.
  - category: Electrophysiological
    name: Generalized Spike-Wave Discharges
    frequency: VERY_FREQUENT
    diagnostic: true
    description: >-
      The interictal EEG shows bilaterally synchronous generalized spike-wave and
      polyspike-wave discharges on a normal background. Discharges were present on
      the very first EEG in 88% of patients in a prospective cohort using
      sleep-deprived recordings. Slow spike-wave below 2.5 Hz is not part of this
      syndrome and its presence should prompt reconsideration of the diagnosis.
    phenotype_term:
      preferred_term: EEG with spike-wave complexes
      term:
        id: HP:0010850
        label: EEG with spike-wave complexes
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Generalized spike-wave discharges (GSWD) were present in the initial EEG
          of 88% of patients.
        explanation: >-
          Directly quantifies generalized spike-wave discharges in an EGTCA
          cohort. 88% falls in the 80-100% band supporting VERY_FREQUENT.
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: OTHER
        snippet: >-
          with 2.5-5.5 Hz generalized spike-wave
        explanation: >-
          Gives the ILAE frequency band for the generalized spike-wave activity expected
          across this syndrome group. Graded INDIRECT because the sentence it comes from
          defines the residual genetic generalized epilepsy category rather than EGTCA
          specifically, though the same discharge band applies.
  - category: Electrophysiological
    name: Photoparoxysmal EEG Response
    frequency: FREQUENT
    description: >-
      A photoparoxysmal response to intermittent photic stimulation is common in
      EGTCA and its detection depends heavily on how many EEGs are recorded: about
      20% on the initial study, rising to about 35% across all follow-up
      recordings in the prospective ILAE-criteria cohort. Reported frequencies
      across the literature span a wide range. It is one route by which photic
      stimulation acts as a seizure precipitant.
    phenotype_term:
      preferred_term: EEG with photoparoxysmal response
      term:
        id: HP:0010852
        label: EEG with photoparoxysmal response
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          A photoparoxysmal response was elicited on the initial EEG of 18
          patients (20.2%) and in 31 patients (34.8%) when all follow-up EEGs are
          considered.
        explanation: >-
          EGTCA-specific rates under 2022 ILAE criteria. The cumulative 34.8%
          falls in the 30-79% band and is the basis for FREQUENT; the 20.2%
          single-EEG figure is why the description separates the two.
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Photosensitivity is common in EGTCA, with reported frequencies ranging
          from 13% to 62%.
        explanation: >-
          Gives the literature range, which spans the OCCASIONAL and FREQUENT
          bands and is why this entry cites a cohort figure rather than asserting
          a precise rate.
      - reference: PMID:11442158
        reference_title: >-
          Photosensitivity in relation to epileptic syndromes: asurvey from an
          epilepsy center in Japan.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          PPR accounted for 17.4% (p < 0.01) of the patients with juvenile
          myoclonic epilepsy, 7.6% (p < 0.01) of those with grand mal on
          awakening, and 6.1% (p < 0.01) of those with symptomatic occipital lobe
          epilepsy.
        explanation: >-
          Useful only for the relative comparison with juvenile myoclonic epilepsy.
          Graded INDIRECT, and NOT used to set the frequency band, because it counts the
          pre-2022 "grand mal on awakening" entity rather than EGTCA, and because the
          same paper notes its cohort's photoparoxysmal rate was low relative to
          European series.
  - category: Neurological
    name: Normal Interictal Neurological and Cognitive Status
    frequency: VERY_FREQUENT
    description: >-
      Development, neurological examination, and global cognition are normal, and
      the EEG background is normal between discharges. This is a defining negative
      feature separating the idiopathic generalized epilepsies from the
      developmental and epileptic encephalopathies, and it is curated explicitly
      because its absence should trigger a search for an alternative diagnosis.
      Subtle executive and attentional differences are described across the IGE
      class but are not part of the syndrome definition.
    phenotype_term:
      preferred_term: Normal interictal neurological and cognitive status
    notes: >-
      No ontology term is bound here on purpose. HPO has no positive term for
      normal interictal status, and binding this to the syndrome's seizure term
      (as an earlier draft did) would export a false assertion. Omitting `term:`
      is the established pattern in this repository for a phenotype the ontology
      cannot express.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Four patients (4.5%) were diagnosed with mild developmental delay and
          five patients (5.6%) had concomitant psychiatric comorbidity,
          predominantly depression and/or anxiety disorder.
        explanation: >-
          Quantifies the exception rather than the rule: 4.5% with developmental
          delay implies roughly 95% with normal development in an EGTCA cohort,
          which is the basis for the VERY_FREQUENT band. It also shows the claim
          is about development and cognition, not about freedom from psychiatric
          comorbidity.
      - reference: PMID:38165295
        reference_title: >-
          Idiopathic Generalized Epilepsy: Misunderstandings, Challenges, and
          Opportunities.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: OTHER
        snippet: >-
          Emerging evidence reveals that patients with IGE may go undiagnosed or
          misdiagnosed with focal epilepsy if EEG or semiology have asymmetric or
          focal features.
        explanation: >-
          Supports the diagnostic importance of the expected normal, symmetric,
          non-focal picture by describing what happens when it is departed from. Graded
          INDIRECT because it evidences the diagnostic consequence rather than
          quantifying normal status, and evidence_source is OTHER because this is a
          review.
  - category: Neurological
    name: Absence Seizures Absent
    frequency: EXCLUDED
    diagnostic: true
    description: >-
      A defining exclusion. Patients have no absence seizures; their presence
      reclassifies the patient as juvenile absence epilepsy, childhood absence
      epilepsy, or unclassified genetic generalized epilepsy. This negative
      criterion is curated as an explicit phenotype rather than left implicit
      because it is part of what makes EGTCA a separate entity.
    phenotype_term:
      preferred_term: Absence seizure
      term:
        id: HP:0002121
        label: Generalized non-motor (absence) seizure
      modifier: ABSENT
    notes: >-
      This descriptor and the myoclonic one below use `modifier: ABSENT` on the
      excluded seizure type rather than reusing the syndrome's own seizure term.
      An earlier draft bound both exclusions to HP:0002069, which is semantically
      backwards: it asserted bilateral tonic-clonic seizure three times over
      instead of stating what is absent. The two exclusions are also split into
      separate phenotypes so each carries its own term rather than being bundled.
      The absence is carried by `frequency: EXCLUDED`, which is what the HPOA
      exporter reads to emit a NOT-qualified row; `modifier: ABSENT` alone is not
      consulted by the export layer and documents intent only.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Patients that do not fulfill criteria for one of these syndromes, but
          that have one, or a combination, of the following generalized seizure
          types: absence, myoclonic, tonic-clonic and myoclonic-tonic-clonic
          seizures, with 2.5-5.5 Hz generalized spike-wave should be classified as
          having GGE.
        explanation: >-
          Establishes that seizure-type combination is what partitions this
          syndrome group, and that patients falling outside the four defined
          syndromes go to the residual GGE category rather than into EGTCA.
          Evidence source is OTHER because this is a consensus position statement.
  - category: Neurological
    name: Myoclonic Seizures Absent
    frequency: EXCLUDED
    diagnostic: true
    description: >-
      The second defining exclusion. Patients have no myoclonic jerks; their
      presence reclassifies the patient as juvenile myoclonic epilepsy or another
      generalized epilepsy. This exclusion is what makes the sodium-channel-blocker
      aggravation literature apply differently in EGTCA than in the sibling
      syndromes, since that literature concerns aggravation of myoclonic and
      absence seizures specifically.
    phenotype_term:
      preferred_term: Myoclonic seizure
      term:
        id: HP:0032794
        label: Myoclonic seizure
      modifier: ABSENT
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Patients that do not fulfill criteria for one of these syndromes, but
          that have one, or a combination, of the following generalized seizure
          types: absence, myoclonic, tonic-clonic and myoclonic-tonic-clonic
          seizures, with 2.5-5.5 Hz generalized spike-wave should be classified as
          having GGE.
        explanation: >-
          Same partitioning rule as for the absence exclusion: myoclonic seizures
          move a patient out of EGTCA. Evidence source is OTHER because this is a
          consensus position statement.
genetic:
  - name: CLCN2
    relationship_type: SUSCEPTIBILITY
    gene_term:
      preferred_term: CLCN2
      term:
        id: hgnc:2020
        label: CLCN2
    notes: >-
      CLCN2 encodes the voltage-gated chloride channel ClC-2 and is the most
      frequently discussed candidate gene in the idiopathic generalized epilepsy
      literature, including generalized tonic-clonic phenotypes. Its role is
      genuinely contested and is curated as susceptibility rather than causation:
      identified missense variants accelerate channel deactivation, but they fail
      to segregate with disease and are transmitted by unaffected parents, and an
      independent screening series found no definite mutations. An early
      CLCN2-epilepsy report was subsequently retracted. This entry cites the gene
      as a susceptibility factor with the disconfirming evidence attached rather
      than omitting it.
    evidence:
      - reference: PMID:19191339
        reference_title: >-
          Two novel CLCN2 mutations accelerating chloride channel deactivation are
          associated with idiopathic generalized epilepsy.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: IN_VITRO
        snippet: >-
          Functional characterization of mutant channels using heterologous
          expression in mammalian cells and whole-cell patch-clamp recordings
          revealed faster deactivation kinetics as the major phenotype of both
          missense mutations.
        explanation: >-
          Establishes a measured functional consequence for the candidate variants.
          Graded INDIRECT, and IN_VITRO, because the electrophysiology was done in a
          heterologous expression system and demonstrates an altered channel property,
          not a contribution to human EGTCA.
      - reference: PMID:19191339
        reference_title: >-
          Two novel CLCN2 mutations accelerating chloride channel deactivation are
          associated with idiopathic generalized epilepsy.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          They may instead represent susceptibility factors among other so far
          undetected genetic alterations in the respective families.
        explanation: >-
          The authors' own conclusion refutes a causative reading of these
          variants and supports the SUSCEPTIBILITY typing used here.
      - reference: PMID:16932951
        reference_title: >-
          Mutations in the CLCN2 gene are a rare cause of idiopathic generalized
          epilepsy syndromes.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We conclude that mutations in the CLCN2 gene are only a rare cause of
          idiopathic generalized epilepsy.
        explanation: >-
          An independent screening series that found no definite mutations,
          bounding how much of the syndrome CLCN2 can explain.
environmental:
  - name: Sleep deprivation
    exposure_term:
      preferred_term: sleep deprivation
      term:
        id: XCO:0001069
        label: sleep restriction
    description: >-
      Sleep deprivation is the most frequently named precipitant among EGTCA
      patients who can identify one, and the practical target of lifestyle
      counseling. It should not be over-sold: about half of patients in the
      prospective cohort could identify no trigger at all. It acts by transiently
      lowering seizure threshold in an already hyperexcitable network rather than
      by causing the underlying epilepsy.
    influences_mechanisms:
      - target: Sleep-Wake State Gating of Seizure Threshold
        environmental_effect: EXACERBATES
        causal_link_type: DIRECT
        description: >-
          Sleep loss is the unifying external precipitant across awakening
          epilepsy, acting on the sleep-wake state modulation of seizure
          threshold.
        evidence:
          - reference: PMID:10996562
            reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              The common denominator of external seizures precipitating
              influences is lack of sleep.
            explanation: >-
              Names sleep loss as the common denominator among precipitating
              influences in this syndrome, which is the exacerbating edge asserted
              here.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Forty-six patients (51.7%) were unable to identify a trigger for their
          seizures. Among the remaining 43 patients, the most frequent
          precipitating factors included sleep deprivation reported by 34 patients
          and severe stress reported by nine.
        explanation: >-
          The EGTCA-specific trigger data, and the basis for both halves of the
          description: sleep deprivation dominates among identifiable triggers
          (34 of 43), yet a slight majority of patients identify no trigger at
          all.
      - reference: PMID:24632482
        reference_title: Seizure precipitants (triggering factors) in patients with epilepsy.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Of 104 patients, 97% cited at least one precipitant. Stress, sleep
          deprivation, and fatigue were the most frequently reported precipitants.
        explanation: >-
          Class-level context from a general epilepsy clinic. Marked INDIRECT because
          the population is all-comers rather than EGTCA, and because its 97%
          trigger-identification rate is strikingly higher than the EGTCA cohort's 48%,
          which is a reason to prefer the syndrome-specific figure.
  - name: Habitual late and unstable sleep pattern
    description: >-
      Beyond acute sleep loss, patients with awakening epilepsy have been
      characterized as late sleepers and late risers whose habitual schedule
      predisposes to chronic sleep debt, with polygraphic evidence of less stable
      sleep. This is a chronic predisposing exposure distinct from an acute
      precipitant, which is why it is typed PREDISPOSES rather than EXACERBATES.
    influences_mechanisms:
      - target: Sleep-Wake State Gating of Seizure Threshold
        environmental_effect: PREDISPOSES
        causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
        description: >-
          A habitually late and unstable sleep schedule maintains a chronic sleep
          deficit that keeps the state-gated seizure threshold persistently lower.
        evidence:
          - reference: PMID:10996562
            reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              The sleep habits of patients with AE who could roughly be
              characterized as late sleepers and late risers may dispose them to a
              chronic sleep deficit.
            explanation: >-
              Directly asserts the predisposing role of habitual sleep timing,
              hedged by the source's own "may dispose", which the PREDISPOSES
              typing preserves.
    evidence:
      - reference: PMID:10996562
        reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The sleep habits of patients with AE who could roughly be
          characterized as late sleepers and late risers may dispose them to a
          chronic sleep deficit.
        explanation: >-
          Attributes the chronic sleep debt in this syndrome to habitual sleep
          timing rather than to any single night of lost sleep, which is what
          makes the habitual pattern an exposure in its own right.
treatments:
  - name: Valproate
    description: >-
      Sodium valproate is the reference first-line agent for generalized
      tonic-clonic seizures in the idiopathic generalized epilepsies and the
      comparator against which alternatives are judged; it was the initial drug
      for 68% of patients in the prospective EGTCA cohort. In a randomized
      non-inferiority trial in newly diagnosed generalized and unclassifiable
      epilepsy, levetiracetam failed to demonstrate non-inferiority to valproate.
      Its use is constrained by teratogenicity, so it is avoided in people of
      childbearing potential where an alternative is viable, and that trade-off is
      a shared decision rather than an automatic exclusion.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: valproic acid
          term:
            id: CHEBI:39867
            label: valproic acid
    target_mechanisms:
      - target: Recurrent Unprovoked Generalized Tonic-Clonic Seizures
        treatment_effect: INHIBITS
        description: >-
          Valproate suppresses the clinical seizure output rather than correcting
          the underlying polygenic susceptibility, which is why relapse is common
          on withdrawal.
        evidence:
          - reference: PMID:38819591
            reference_title: >-
              Prospective study of epilepsy with generalized tonic-clonic seizures
              alone: Clinical features, response to treatment, and likelihood of
              medication withdrawal.
            supports: SUPPORT
            directness: INDIRECT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              A GTC recurred in 14% of patients treated with ASM compared with 73%
              of untreated patients (p < 0.00001).
            explanation: >-
              The best available EGTCA-specific evidence that pharmacotherapy suppresses
              seizure recurrence, in a cohort where valproate was the initial agent for
              68% of patients. Graded INDIRECT because the contrast is treated versus
              untreated rather than valproate versus another drug, so it cannot isolate
              valproate's contribution.
          - reference: PMID:32030724
            reference_title: >-
              Tonic-clonic seizures in idiopathic generalized epilepsies:
              Prevalence, risk factors, and outcome.
            supports: SUPPORT
            directness: INDIRECT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              Valproate reduced the risk of experiencing GTCSs significantly (OR:
              0.58; 95% CI: 0.34-0.99; P = .04).
            explanation: >-
              Marked INDIRECT, and deliberately not used as the primary support, because
              the outcome modeled is whether an IGE patient has generalized tonic-clonic
              seizures at all. The comparison group is IGE patients without such
              seizures, mostly absence and myoclonic syndromes, so within EGTCA - where
              every patient has them by definition - this odds ratio cannot describe a
              treatment effect. It is retained as class-level context only, and the
              causal reading in an earlier draft of this explanation was withdrawn.
    evidence:
      - reference: PMID:33838758
        reference_title: "The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Levetiracetam did not meet the criteria for non-inferiority in the ITT
          analysis of time to 12-month remission
        explanation: >-
          Randomized trial evidence that the leading alternative failed to match
          valproate, which is the basis for retaining valproate as the reference
          first-line agent.
      - reference: PMID:33838758
        reference_title: "The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial."
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Valproate is a first-line treatment for patients with newly diagnosed
          idiopathic generalised or difficult to classify epilepsy, but not for
          women of child-bearing potential because of teratogenicity.
        explanation: >-
          States the teratogenicity constraint that governs prescribing. Graded INDIRECT
          because this is the trial's background framing rather than a teratogenicity
          result generated by the trial itself.
  - name: Levetiracetam
    description: >-
      Levetiracetam is the most commonly used alternative to valproate and is
      preferred in people of childbearing potential because of its substantially
      lower teratogenic risk. The honest framing is that this is a trade-off
      rather than an equivalence: SANAD II found levetiracetam neither
      non-inferior nor cost-effective against valproate, so the choice buys
      reproductive safety at some cost in seizure control.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: levetiracetam
          term:
            id: CHEBI:6437
            label: levetiracetam
    target_mechanisms:
      - target: Recurrent Unprovoked Generalized Tonic-Clonic Seizures
        treatment_effect: INHIBITS
        description: >-
          Suppression of clinical seizure output, with the same
          non-disease-modifying caveat as valproate.
        evidence:
          - reference: PMID:38819591
            reference_title: >-
              Prospective study of epilepsy with generalized tonic-clonic seizures
              alone: Clinical features, response to treatment, and likelihood of
              medication withdrawal.
            supports: SUPPORT
            directness: INDIRECT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              A GTC recurred in 14% of patients treated with ASM compared with 73%
              of untreated patients (p < 0.00001).
            explanation: >-
              Demonstrates that antiseizure medication as a class suppresses seizure
              recurrence in EGTCA specifically. Graded INDIRECT because the comparison
              is treated versus untreated rather than levetiracetam-specific.
    evidence:
      - reference: PMID:33838758
        reference_title: "The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial."
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          For girls and women of child-bearing potential, these results inform
          discussions about benefit and harm of avoiding valproate.
        explanation: >-
          Frames the levetiracetam choice as a benefit-harm discussion rather than a
          straightforward substitution. Graded INDIRECT because it supports the decision
          framing rather than establishing levetiracetam efficacy.
  - name: Lamotrigine
    description: >-
      Lamotrigine is an alternative broad-spectrum option for generalized
      tonic-clonic seizures with low teratogenic risk, requiring slow titration
      because of rash risk and dose adjustment when combined with valproate, which
      inhibits its metabolism.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: lamotrigine
          term:
            id: CHEBI:6367
            label: lamotrigine
    notes: >-
      No EGTCA-specific efficacy trial was identified for lamotrigine during
      curation, so this treatment carries a description and an agent binding but
      no evidence item asserting syndrome-level efficacy. Recorded as a curation
      gap rather than propped up with a citation that does not make the claim.
  - name: Sleep hygiene and precipitant avoidance counseling
    description: >-
      Regularizing sleep schedule, avoiding sleep deprivation, and moderating
      alcohol are the non-pharmacological cornerstone of management, and follow
      directly from the syndrome's defining sensitivity to sleep-wake state. This
      is the one intervention that acts on the modulating input rather than on the
      seizure output.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: Supportive Care
      term:
        id: NCIT:C15747
        label: Supportive Care
    target_mechanisms:
      - target: Sleep-Wake State Gating of Seizure Threshold
        treatment_effect: INHIBITS
        description: >-
          Removing the precipitant removes the transient threshold reduction that
          converts a hyperexcitable network into a clinical seizure.
        evidence:
          - reference: PMID:10996562
            reference_title: Epilepsy with grand mal on awakening and sleep-waking cycle.
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              The common denominator of external seizures precipitating
              influences is lack of sleep.
            explanation: >-
              Identifies the modifiable precipitant that this intervention targets. No
              trial evidence was identified showing that counseling changes seizure
              outcomes in EGTCA.
progression:
  - phase: Early treatment response
    age_range: Adolescence to young adulthood
    notes: >-
      EGTCA is among the more manageable idiopathic generalized epilepsies. Most
      patients respond promptly to antiseizure medication and drug resistance is
      uncommon at 16.3% in the largest cohort, but a substantial minority follow a
      relapsing-remitting course rather than a clean remission, so the syndrome
      should not be described as uniformly benign.
    evidence:
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Drug resistance at the last visit was observed in 40 (16.3%) patients
        explanation: >-
          Puts a number on the "drug resistance is uncommon" claim rather than
          leaving it qualitative.
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          had no-remission and relapsing-remitting patterns, respectively.
        explanation: >-
          Anchors the relapsing-remitting subgroup, which in that cohort was 36.3%
          of patients followed at least five years, against 8% with no remission.
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          GTCA could be considered a relatively easily manageable IGE syndrome,
          with a low rate of drug resistance and a high prevalence of early
          response to treatment.
        explanation: >-
          Multicenter confirmation of the favorable treatment-response profile in
          a cohort defined by the 2022 ILAE criteria.
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Nevertheless, a considerable proportion of patients experience relapsing
          patterns of seizure control, highlighting the need for appropriate
          counseling and lifestyle recommendations.
        explanation: >-
          Bounds the favorable framing by documenting the relapsing-remitting
          subgroup.
  - phase: Attempted medication withdrawal
    age_range: Young adulthood onward
    notes: >-
      Lifelong treatment is not always necessary, but relapse after withdrawal is
      frequent, and the two ILAE-criteria cohorts disagree sharply on how frequent:
      44% recurrence in the prospective cohort versus 83% in the larger
      retrospective one. That gap is not resolved here and should not be averaged
      away; it plausibly reflects differences in follow-up duration, in who was
      selected for a withdrawal attempt, and in how recurrence was ascertained.
      The predictors also differ by cohort. The prospective cohort found
      patient-initiated tapering and a mixed diurnal-nocturnal seizure pattern
      independently predicted recurrence, and reported success where seizure
      freedom was long-standing and generalized spike-wave had resolved; the
      retrospective cohort found longer seizure freedom to be the only predictor of
      successful withdrawal. The circadian predictor links prognosis back to the
      sleep-wake gating node in the pathophysiology.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          ASM discontinuation was attempted in 50 patients after a median
          treatment duration of 3 years, with 44% experiencing a recurrence.
        explanation: >-
          Quantifies relapse risk on withdrawal in an EGTCA-specific prospective
          cohort.
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Patient-initiated taper and a mixed circadian seizure pattern
          independently predicted a higher likelihood of recurrence post-ASM
          discontinuation.
        explanation: >-
          Identifies the two independent predictors of relapse, including the
          circadian pattern that ties prognosis to the sleep-wake gating node.
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          At the last visit, 49 (83%) of those patients had experienced GTCS
          recurrence.
        explanation: >-
          The competing relapse estimate. Curated alongside the 44% figure rather
          than in place of it, because the two ILAE-criteria cohorts genuinely
          disagree and picking one would misrepresent the state of the evidence.
      - reference: PMID:37872695
        reference_title: >-
          Epilepsy with generalized tonic-clonic seizures alone: Electroclinical
          features and prognostic patterns.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          A longer duration of seizure freedom was the only factor predicting a
          higher chance of successful ASM withdrawal according to multivariable
          Cox regression.
        explanation: >-
          The competing predictor set. Note "the only factor", which sits in
          tension with the prospective cohort's additional predictors and is why
          the notes attribute predictors to specific cohorts rather than merging
          them into one list.
  - phase: Long-term outcome
    age_range: Adulthood to late adulthood
    notes: >-
      Over decades of follow-up, long-term seizure outcome in EGTCA is very
      similar to that of the other adolescent-onset generalized genetic
      epilepsies, with most patients reaching terminal remission. Age at first
      seizure is the feature that most clearly separates EGTCA from juvenile
      absence and juvenile myoclonic epilepsy, being several years later.
    evidence:
      - reference: PMID:28464258
        reference_title: Long-term outcome in adolescent-onset generalized genetic epilepsies.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Age at first seizure was significantly higher in EGTCS patients (median
          18 years) than in patients with JAE or JME (14 years each; p ≤ 0.001).
        explanation: >-
          Establishes the later onset of EGTCA relative to its sibling syndromes
          in a cohort with a median 42.5-year follow-up.
      - reference: PMID:28464258
        reference_title: Long-term outcome in adolescent-onset generalized genetic epilepsies.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Long-term outcome was shown to be highly similar across all subsyndromes
          of adolescent-onset GGE.
        explanation: >-
          Supports curating long-term prognosis at the adolescent-onset GGE level
          rather than asserting an EGTCA-specific long-term trajectory.
prevalence:
  - population: Patients diagnosed with an idiopathic generalized epilepsy
    measure_type: UNKNOWN
    prevalence_class: UNKNOWN
    notes: >-
      Recorded as a share of idiopathic generalized epilepsy diagnoses rather than
      as a population rate. Reported proportions vary widely across cohorts and
      diagnostic eras, so no population rate is asserted here; the 31% figure is
      from a single prospective center applying mandatory ILAE criteria and should
      not be read as a general population estimate. measure_type is UNKNOWN rather
      than POINT_PREVALENCE on purpose: this is a share of a diagnostic group, and
      PrevalenceMeasureEnum has no value for that, so claiming a point prevalence
      would misdescribe the statistic.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Eighty-nine patients with a median age of 16 years were included,
          constituting 31% of those diagnosed with an idiopathic generalized
          epilepsy.
        explanation: >-
          Gives the syndrome's share of idiopathic generalized epilepsy diagnoses
          in a prospective multicenter cohort using mandatory ILAE criteria.
  - population: All epilepsies
    measure_type: UNKNOWN
    prevalence_class: UNKNOWN
    notes: >-
      Class-level context only. The idiopathic generalized epilepsies as a group
      account for roughly a fifth of all epilepsies; EGTCA is one of four
      syndromes within that fifth, and no reliable syndrome-level population rate
      was identified during curation. As above, measure_type is UNKNOWN because
      this records a share of all epilepsies, not a population rate for EGTCA.
    evidence:
      - reference: PMID:38165295
        reference_title: >-
          Idiopathic Generalized Epilepsy: Misunderstandings, Challenges, and
          Opportunities.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: OTHER
        snippet: >-
          The idiopathic generalized epilepsies (IGE) make up a fifth of all
          epilepsies, but <1% of epilepsy research.
        explanation: >-
          Establishes the class-level share of all epilepsies. Marked INDIRECT because
          it covers the four-syndrome group rather than EGTCA alone, and evidence_source
          is OTHER because this is a review.
diagnosis:
  - name: Sleep-deprived EEG with serial recording
    description: >-
      Generalized spike-wave discharge is mandatory for the diagnosis, so the EEG
      protocol is not incidental to it. A 3-hour sleep-deprived recording captured
      discharges in 88% of patients on the first study in the prospective cohort,
      and repeating the EEG recovered most of the remainder. A single normal
      routine EEG therefore does not exclude EGTCA, and serial sleep-deprived
      recordings are the practical standard.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Participants underwent a 3-h sleep-deprived video-EEG recording along
          with an epilepsy protocol brain magnetic resonance imaging (MRI) with
          repeat EEG at each follow-up.
        explanation: >-
          Documents the diagnostic protocol under which the cohort's 88%
          first-EEG yield was obtained, which is what makes that figure
          actionable rather than abstract.
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The significance of these findings is underscored by the mandatory
          presence of GSWD for diagnosing EGTCA.
        explanation: >-
          Establishes that the EEG finding is a required diagnostic criterion, not
          merely supportive, which is why EEG yield matters so much in this
          syndrome.
  - name: MRI to exclude a structural lesion
    description: >-
      Brain MRI is performed to exclude a structural cause rather than to confirm
      EGTCA; the syndrome is non-lesional by definition. Focal slowing or a
      persistent focal EEG abnormality should prompt reconsideration of the
      diagnosis rather than reassurance.
    evidence:
      - reference: PMID:38819591
        reference_title: >-
          Prospective study of epilepsy with generalized tonic-clonic seizures
          alone: Clinical features, response to treatment, and likelihood of
          medication withdrawal.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          along with an epilepsy protocol brain magnetic resonance imaging (MRI)
        explanation: >-
          Confirms that dedicated epilepsy-protocol MRI was part of the diagnostic
          workup in the ILAE-criteria cohort. Graded INDIRECT because it documents that
          imaging was performed rather than reporting the yield, so it supports the
          practice without quantifying how often a lesion is found.
differential_diagnoses:
  - name: Focal epilepsy with focal to bilateral tonic-clonic seizures
    description: >-
      The most consequential differential, because the two are treated
      differently. Focal epilepsy is distinguished by focal EEG onset, aura or
      focal semiology, and a structural lesion when one is present. The error runs
      in both directions: idiopathic generalized epilepsy is itself misdiagnosed
      as focal epilepsy when EEG or semiology carry asymmetric or focal features.
    evidence:
      - reference: PMID:38165295
        reference_title: >-
          Idiopathic Generalized Epilepsy: Misunderstandings, Challenges, and
          Opportunities.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Emerging evidence reveals that patients with IGE may go undiagnosed or
          misdiagnosed with focal epilepsy if EEG or semiology have asymmetric or
          focal features.
        explanation: >-
          Documents the misdiagnosis risk in the generalized-to-focal direction,
          which is the less commonly taught half of this differential. Evidence
          source is OTHER because this is a review.
  - name: Juvenile myoclonic epilepsy and juvenile absence epilepsy
    description: >-
      The sibling idiopathic generalized epilepsy syndromes, separated from EGTCA
      solely by the presence of myoclonic jerks or absence seizures. Because
      myoclonus may be underreported unless specifically asked about, the
      distinction depends on the quality of the history as much as on the EEG.
    evidence:
      - reference: PMID:35503716
        reference_title: >-
          ILAE definition of the Idiopathic Generalized Epilepsy Syndromes:
          Position statement by the ILAE Task Force on Nosology and Definitions.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          The goal of this paper is to delineate the four syndromes comprising the
          IGEs, namely childhood absence epilepsy, juvenile absence epilepsy,
          juvenile myoclonic epilepsy, and epilepsy with generalized tonic-clonic
          seizures alone.
        explanation: >-
          Establishes the four syndromes as separate entities requiring
          differentiation from one another. Evidence source is OTHER because this
          is a consensus position statement.
  - name: Drug-resistant generalized epilepsy outside the IGE definition
    description: >-
      A meaningful proportion of patients who meet the 2022 IGE criteria on paper
      have refractory seizures or atypical features, and whether these lie inside
      the syndrome's spectrum or represent a distinct entity is unsettled. This
      matters for EGTCA because drug resistance is otherwise uncommon here, so a
      refractory course should prompt reconsideration rather than escalation
      alone.
    evidence:
      - reference: PMID:38508955
        reference_title: >-
          Drug-resistant generalized epilepsies: Revisiting the frontiers of
          idiopathic generalized epilepsies.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          Indeed, among patients presenting with a syndrome compatible with the
          2022 definition of IGEs, we still observe a significant proportion of
          patients presenting with specific clinical features, refractory
          seizures, or drug-resistant epilepsies.
        explanation: >-
          Documents the boundary problem directly. Evidence source is OTHER
          because this is a review article.
discussions:
  - discussion_id: egtca_seizure_type_divergence
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Why does a shared cortico-thalamocortical mechanism produce generalized
      tonic-clonic seizures alone in EGTCA, but absence or myoclonic seizures in
      its sibling syndromes?
    attaches_to:
      - "pathophysiology#Recruitment of Motor Systems into Tonic-Clonic Output"
    rationale: >-
      The four idiopathic generalized epilepsy syndromes are curated as sharing a
      polygenic thalamocortical mechanism, yet they are separated clinically by
      seizure type alone. No mechanistic account was identified during curation
      that explains why the same class of network abnormality yields convulsive
      output alone here and absence or myoclonus elsewhere. The entry therefore
      asserts a difference in network engagement without specifying it, and this
      node is the honest location of that gap.
    proposed_experiments:
      - experiment_id: egtca_cross_syndrome_network_imaging
        name: Cross-syndrome ictal network comparison
        description: >-
          Compare ictal and interictal network dynamics across EGTCA, juvenile
          absence epilepsy, and juvenile myoclonic epilepsy cohorts using one
          shared EEG-fMRI or MEG protocol, testing whether motor-system
          recruitment differs at the point of seizure onset rather than only in
          clinical output.
      - experiment_id: egtca_powered_subtype_gwas
        name: Adequately powered EGTCA-stratified GWAS
        description: >-
          Syndrome-stratified genetic analysis at sample sizes large enough to
          detect an EGTCA-specific locus, given that the 2023 ILAE meta-analysis
          was underpowered for this syndrome at n = 499.
  - discussion_id: egtca_sodium_channel_blocker_caution
    kind: KNOWLEDGE_GAP
    status: OPEN
    prompt: >-
      Does the sodium-channel-blocker aggravation caution that applies across the
      idiopathic generalized epilepsies actually apply to EGTCA, where absence and
      myoclonic seizures are absent by definition?
    attaches_to:
      - "pathophysiology#Recurrent Unprovoked Generalized Tonic-Clonic Seizures"
    rationale: >-
      The evidence base for aggravation by carbamazepine and oxcarbazepine
      concerns myoclonic and absence seizures. In the oxcarbazepine series the
      effect on generalized tonic-clonic seizures was explicitly described as less
      dramatic, with no worsening in half the patients. Since EGTCA patients have
      no myoclonic or absence seizures to aggravate, the standard blanket caution
      may not transfer, but no EGTCA-specific study was identified either way. The
      entry records the uncertainty rather than repeating the generalization or
      asserting safety.
    evidence:
      - reference: PMID:15461683
        reference_title: >-
          Worsening of seizures by oxcarbazepine in juvenile idiopathic
          generalized epilepsies.
        supports: SUPPORT
        directness: INDIRECT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The effects of OXC on GTCSs were less dramatic, with no worsening in
          frequency in three and a slight increase in three.
        explanation: >-
          Shows that the aggravation signal is much weaker for generalized tonic-clonic
          seizures than for the myoclonic and absence seizures that drive the caution.
          Graded INDIRECT because the series contained no EGTCA patients, so this bounds
          the inference rather than resolving it.
      - reference: PMID:15461683
        reference_title: >-
          Worsening of seizures by oxcarbazepine in juvenile idiopathic
          generalized epilepsies.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Aggravation consisted of a clear aggravation of myoclonic jerks (five
          cases) or de novo myoclonic jerks (one case).
        explanation: >-
          Identifies the seizure types actually aggravated, none of which occur in
          EGTCA by definition, which is the basis for questioning the transfer.
  - discussion_id: egtca_absence_model_mismatch
    kind: HUMAN_MODEL_MISMATCH
    status: OPEN
    prompt: >-
      Can absence-epilepsy rodent models be used as mechanistic evidence for
      EGTCA, when they reproduce spike-wave discharge with behavioral arrest
      rather than the awakening-triggered convulsive phenotype that defines the
      syndrome?
    attaches_to:
      - "pathophysiology#Cortico-Thalamocortical Excitation-Inhibition Imbalance"
    rationale: >-
      The rodent models that underpin thalamocortical hypersynchrony theory are
      absence models producing spike-wave discharge with behavioral arrest, and
      none reproduces either the generalized-tonic-clonic-alone seizure output or
      the awakening-linked circadian pattern. Their evidence therefore bears on
      the shared network mechanism, not on what makes EGTCA a distinct syndrome.
      This entry deliberately cites no model-organism evidence for any node, which
      is why the mismatch is recorded here rather than attached to a citation.
    proposed_experiments:
      - experiment_id: egtca_rodent_circadian_convulsive_screen
        name: Circadian convulsive-phenotype screen in GGE rodent lines
        description: >-
          Characterize whether any existing genetic generalized epilepsy rodent
          line shows convulsive seizures clustering around the wake transition,
          and if so whether the circadian gating is separable from the underlying
          spike-wave mechanism.

📚

References & Deep Research

References

3

PMID:35503716

ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.

No top-level findings curated for this source.

PMID:38819591

Prospective study of epilepsy with generalized tonic-clonic seizures alone: Clinical features, response to treatment, and likelihood of medication withdrawal.

No top-level findings curated for this source.

PMID:37872695

Epilepsy with generalized tonic-clonic seizures alone: Electroclinical features and prognostic patterns.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Epilepsy with Generalized Tonic-Clonic Seizures Alone (EGTCSA) — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 21 citations 2026-08-09T02:36:15.309346

Epilepsy with Generalized Tonic-Clonic Seizures Alone (EGTCSA) — Comprehensive Research Report

1. Disease Information

Overview: Epilepsy with generalized tonic-clonic seizures alone (EGTCSA) — historically termed "epilepsy with grand mal on awakening" (Aufwach-Epilepsie, described by Janz in 1953) — is one of the four canonical idiopathic generalized epilepsy (IGE) syndromes, alongside childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), and juvenile myoclonic epilepsy (JME). It is defined by the occurrence of generalized tonic-clonic seizures (GTCS) as the sole seizure type, in a patient with a generalized EEG trait and no structural brain lesion, distinguishing it from JME/JAE where GTCS occur together with myoclonic jerks or absences (Hirsch et al., Epilepsia 2022, PMID for ILAE position statement, doi:10.1111/epi.17236) (Wiley).

Key identifiers: - MONDO: MONDO:0005754 ("Epilepsy with generalized tonic-clonic seizures," the current MONDO umbrella term used for this entity) (BioPortal) - Orphanet: ORPHA:698005 ("Epilepsy with generalized tonic-clonic seizures alone") (Orphanet) - ICD-10: G40.3 (Generalized idiopathic epilepsy and epileptic syndromes) - MeSH: Epilepsy, Generalized (D004829) / Epilepsy, Tonic-Clonic (D004832) - ILAE classification: One of the four Idiopathic Generalized Epilepsy Syndromes (2022 ILAE Nosology Task Force) (ILAE)

Synonyms: Epilepsy with grand mal on awakening; Aufwach-Epilepsie (Janz); Awakening epilepsy; Generalized tonic-clonic seizures on awakening; Pure grand mal epilepsy; formerly abbreviated GMA or EGMA; also loosely "primary generalized tonic-clonic epilepsy."

Data provenance: Information on this syndrome is derived from a mix of individual-patient clinical/EEG cohorts (e.g., Beydoun et al. 2024 prospective cohort, PMC11296088; Asadi-Pooya & Homayoun 2020 retrospective cohort, PMID:32030724) and aggregated syndrome-level nosologic resources (ILAE, Orphanet, epilepsydiagnosis.org/Epilepsy Diagnosis.org "EpilepsyDiagnosis" curated syndrome pages, and MedLink Neurology).

2. Etiology

Disease causal factors: EGTCSA is classified as a genetic/idiopathic generalized epilepsy — presumed genetic etiology without an identifiable structural, metabolic, or acquired cause in the great majority of patients. Genetic architecture is complex/polygenic, not monogenic: "As the genetic etiology is complex/polygenic, pathogenic single gene disorders are not expected and genetic testing is not part of routine clinical evaluation" (epilepsydiagnosis.org, EGTCSA genetics page).

Genetic risk factors: - Polygenic risk / common-variant architecture: GWAS meta-analyses by the ILAE Consortium on Complex Epilepsies identified genome-wide significant loci for genetic generalized epilepsy (GGE) as a class. The 2018 mega-analysis (Nat Commun 2018, PMID for International League Against Epilepsy Consortium GWAS) identified 16 genome-wide loci across common epilepsies with strongest signal in genetic generalized epilepsy (Nature Communications 2018); a larger 2023 meta-analysis (29,944 cases, 52,538 controls) identified 26 risk loci, 19 of which were specific to GGE, implicating 29 likely causal genes (Nat Genet 2023) (Nature Genetics 2023). - Twin studies: Monozygotic twin concordance for IGE substantially exceeds dizygotic concordance (76% vs 33% cited in one review, PMID:9546323), supporting strong heritability (PMC11097769, "Idiopathic Generalized Epilepsy: Misunderstandings, Challenges, and Opportunities," PMID:38165295). - Candidate/rare-variant genes reported across the IGE spectrum (not EGTCSA-specific, but implicated in the broader syndrome group EGTCSA belongs to): - CLCN2 (voltage-gated chloride channel ClC-2, hgnc gene) — variants reported in IGE families including EGTCSA/GTCS phenotypes, though causality remains controversial: Saint-Martin et al. 2009 (Hum Mutat, PMID:19191339) identified two novel CLCN2 missense mutations (p.Arg235Gln, p.Arg577Gln) with accelerated channel deactivation kinetics in IGE families; Niemeyer et al. (PMID:15252188) performed functional characterization of ClC-2 IGE-associated mutants; but Saint-Martin et al. 2007 (PMID:16932951) concluded CLCN2 mutations are only a rare cause, and a subsequent study found "no evidence for a role of CLCN2 variants in idiopathic generalized epilepsy" (Nat Genet 2010) — an earlier 2003 CLCN2 paper was later retracted. - CACNB4 (calcium channel beta-4 subunit), CACNA1A/CACNA1G/CACNA1H (calcium channel alpha subunits/T-type channels), GABRA1, GABRB3, GABRG2, GABRD (GABA-A receptor subunits), EFHC1 (myoclonin-1) — all reported across the IGE/JME spectrum (PMC11097769); no single gene is established as causal specifically for EGTCSA. - BRD2 (6p21.3) and connexin-36/GJD2 — reported associations with JME. - Copy number variants: Recurrent microdeletions 15q11.2, 15q13.3, and 16p13.11 are recommended for screening via chromosomal microarray specifically when EGTCSA is drug-resistant or accompanied by intellectual disability (epilepsydiagnosis.org genetics page). - Family history: A first-degree family history of epilepsy is present in roughly 2 in 10 patients ("in keeping with complex inheritance"), with affected relatives typically having other IGE/genetic generalized epilepsy phenotypes rather than EGTCSA specifically. Family history of febrile seizures is reported in ~1 in 10 patients (epilepsydiagnosis.org overview page).

Environmental risk factors / precipitants (function as seizure triggers/provocateurs rather than root causes in a genetically susceptible individual): - Sleep deprivation — the dominant and best-documented trigger. - Fatigue. - Alcohol use/withdrawal. - Sleep-wake transitions — seizures cluster in the 1–2 hours after awakening (hence the historical name), and to a lesser extent in a second peak during evening relaxation ("at leisure time"). - Photic stimulation — a photoparoxysmal EEG response is documented on repeat EEG testing in up to 35% of EGTCSA patients (Beydoun et al. 2024, PMC11296088), and clinical photosensitivity is a recognized precipitant in the broader IGE group.

Protective factors: No specific genetic or environmental protective factors are documented for EGTCSA in the literature surveyed; general seizure-threshold-raising behaviors (regular sleep, alcohol avoidance) are protective against triggering seizures in a susceptible individual but do not alter underlying genetic risk.

Gene-environment interactions: The prevailing model is a polygenic susceptibility threshold modulated by environmental state-dependent factors (sleep deprivation, circadian phase, alcohol) that transiently lower seizure threshold in genetically predisposed thalamocortical networks — consistent with the "system epilepsy" framework in which seizure timing (awakening) reflects an interaction between genetic network hyperexcitability and the sleep-wake cycle rather than a discrete lesion (Janz 2000, Clin Neurophysiol 111 Suppl 2:S103-10, PMID:10996562).

3. Phenotypes

Core phenotype — Generalized Tonic-Clonic Seizure (the defining and, by definition, only seizure type): - HPO term suggestion: HP:0002069 (Generalized tonic-clonic seizures); broader parent HP:0032661 (Generalized-onset seizure) / HP:0001250 (Seizure). - Type: Clinical sign/seizure semiology. - Onset: Peak in the second decade; overall range 5–40 years, with ~80% starting between ages 11–23 (typically cited as 10–25 years) (epilepsydiagnosis.org overview; epilepsy.com syndrome page). In the Beydoun 2024 cohort (n=89), median age at onset was 16 years. - Severity: Seizures are typically infrequent (in contrast to the more frequent seizures of JME or CAE) but are, by definition, convulsive and carry injury/SUDEP risk. - Timing pattern: Predominantly diurnal, shortly after awakening (within 1–2 hours of waking, independent of clock time) or during relaxation/"leisure time" in the evening. In the Beydoun cohort, 59.6% had exclusively diurnal seizures, 28.1% had a mixed diurnal/nocturnal pattern, and a mixed circadian pattern was itself an independent predictor of relapse after medication withdrawal. - Progression: Typically stable/non-progressive in cognitive terms; seizure frequency is usually low and episodic, often triggered rather than spontaneous. - Frequency among affected individuals: By definition 100% (this is the defining/only phenotype), though the diagnosis requires exclusion of absence and myoclonic seizures.

Associated/secondary features: - Normal neurological examination and head circumference (epilepsydiagnosis.org). - Normal antecedent/birth history; possible prior febrile seizures. - Cognitive profile: Typically normal global development and intelligence, though subtle deficits in executive function and attention may be present in a subset — consistent with the broader IGE literature showing a distinct neuropsychological profile of impaired executive function and reduced psychomotor speed with preserved memory across IGE syndromes (NBK546611). - Psychiatric comorbidity (extrapolated from IGE-wide data, not EGTCSA-specific): Psychiatric comorbidities affect an estimated ~75% of people with epilepsy broadly, with depression (~55%) and anxiety (~25–50%) most common; comorbidity contributes to premature mortality in epilepsy independent of seizure control (Lancet 2013 population study; PMC9433706).

Quality of life impact: Not separately quantified for EGTCSA in the sources reviewed; IGE-wide data show reduced quality of life associated with poor seizure control, psychiatric comorbidity, and unemployment (PMC11097769). Recurrent GTCS carry a documented 40–60% risk of seizure-related bodily injury (burns, fractures, concussion) at 12-month follow-up in generalized epilepsy cohorts (NBK546611).

HPO term summary for KB curation: | Phenotype | Suggested HPO term | |---|---| | Generalized tonic-clonic seizure | HP:0002069 | | Seizures related to sleep-wake cycle / on awakening | (no precise HPO term; capture via temporality/description) | | Photoparoxysmal EEG response | HP:0010819 (Photoparoxysmal response) | | Executive dysfunction | HP:0031331 (Impaired executive functioning) — verify exact label via OAK | | Generalized spike-wave discharges | HP:0011182 (Generalized non-motor seizure with impairment of consciousness — not exact; better modeled as an EEG/laboratory finding, e.g., HP:0002353 EEG abnormality) |

4. Genetic/Molecular Information

Causal genes: None established as monogenic causes specific to EGTCSA. The syndrome is explicitly modeled as polygenic/complex, and "pathogenic single gene disorders are not expected" (epilepsydiagnosis.org). This distinguishes EGTCSA from monogenic epilepsy syndromes and from GEFS+ (Genetic Epilepsy with Febrile Seizures Plus), a related but phenotypically and often genetically distinct spectrum (SCN1A, SCN1B, GABRG2 etc.) that includes febrile seizures as a defining feature.
Candidate genes reported in the broader IGE/GTCS literature (association-level evidence, not disease-causing in the Mendelian sense):
CLCN2 (chloride channel 2) — see Etiology section; controversial, retracted early report, later studies show inconsistent replication.
CACNB4, CACNA1A, CACNA1G, CACNA1H — calcium channel subunits, implicated in T-type calcium current dysregulation central to thalamocortical hypersynchronization models.
GABRA1, GABRB3, GABRG2, GABRD — GABA-A receptor subunit genes.
EFHC1 (myoclonin-1) — primarily JME-associated.
BRD2 — JME-associated polymorphism.
Variant classification/pathogenicity: Not routinely applicable — genetic testing (single-gene, panel) is not part of routine clinical evaluation for EGTCSA given the polygenic model; ClinVar/ACMG-AMP classification frameworks are relevant mainly for the rare monogenic look-alikes that must be excluded (e.g., SCN1A-related disorders) rather than for EGTCSA itself.
Allele frequency in population databases: Not meaningfully defined for a polygenic trait; individual candidate-gene rare variants (e.g., CLCN2 missense variants) have been reported at low frequency in family-based cohorts, not systematically characterized in gnomAD for this specific phenotype.
Somatic vs germline: Germline (heritable) susceptibility model; no somatic mosaicism mechanism reported.
Functional consequences: For CLCN2 candidate variants, functional electrophysiology (whole-cell patch clamp in heterologous expression systems) showed accelerated channel deactivation kinetics (gain-of-function-like altered gating) as the proposed mechanism (Saint-Martin 2009, PMID:19191339; Niemeyer, PMID:15252188).
Copy number variants / chromosomal abnormalities: Recurrent CNVs 15q11.2, 15q13.3, 16p13.11 microdeletions are recommended targets for chromosomal microarray testing in drug-resistant or cognitively-impaired EGTCSA presentations — these are well-established generalized-epilepsy risk CNVs across the IGE spectrum, not EGTCSA-specific.
Epigenetic information: No EGTCSA-specific epigenetic (DNA methylation/histone) data were identified in the sources reviewed.
GWAS/polygenic architecture: The ILAE Consortium on Complex Epilepsies' 2018 (16 loci, Nat Commun, PMID for study cohort 14,534 cases/24,218 controls) and 2023 (26 loci, 19 GGE-specific, 29 candidate genes, Nat Genet 2023) meta-analyses are the principal genome-wide resources; these studies pool across the four IGE syndromes rather than isolating EGTCSA as a distinct GWAS stratum.

Suggested gene/ontology annotations for KB curation (candidate-association tier, not causal): - hgnc:2020 (CLCN2), hgnc:1402 (CACNB4), hgnc:4075 (GABRA1), hgnc:4088 (GABRD), hgnc:4093 (GABRG2), hgnc:4086 (GABRB3) — verify exact HGNC IDs via lookup before use. - GO terms: "chloride channel activity" (GO:0005254), "voltage-gated calcium channel activity" (GO:0005245), "GABA-A receptor complex" (GO:1902711).

5. Environmental Information

Environmental factors: No toxin, chemical, occupational, or infectious cause is implicated in EGTCSA pathogenesis; it is not an acquired/symptomatic epilepsy.
Lifestyle factors (functioning as seizure precipitants, not causal agents):
Sleep deprivation (best-established trigger; central to historical nosology "epilepsy with grand mal on awakening").
Alcohol consumption/withdrawal.
Fatigue/physical or psychological stress.
Irregular sleep-wake schedules (shift work, jet lag).
Infectious agents: Not applicable — EGTCSA is not an infection-triggered or post-infectious epilepsy syndrome.

6. Mechanism / Pathophysiology

Causal chain (thalamocortical network model, shared across IGE syndromes; EGTCSA-specific granularity is limited in the literature):

Trigger/molecular substrate: Polygenic dysregulation of ion channels controlling thalamocortical excitability — particularly T-type calcium channels (CACNA1G/H), GABA-A receptor subunits, and candidate chloride channel (CLCN2) function — sets a lowered seizure threshold.
Cellular process: Altered tonic and phasic GABA-A-mediated inhibition in thalamocortical relay neurons and T-type calcium current dynamics in thalamic reticular/relay neurons promote pathological oscillatory burst-firing.
Circuit-level process: Cortico-thalamo-cortical hypersynchronization generates generalized spike-wave discharges (GSWD); in animal absence-epilepsy models (GAERS rats, stargazer mice, Gria4/AMPA-receptor-deficient models), spike-wave discharges originate in layer 5/6 somatosensory cortical neurons and propagate to thalamus via reciprocal cortico-thalamic loops (multiple PMC sources on GAERS/stargazer pathophysiology).
State-dependent modulation: Sleep-wake transition physiology (changing thalamocortical arousal state, altered GABAergic tone during drowsiness/sleep) interacts with this hyperexcitable network to concentrate seizure occurrence around awakening — the mechanistic basis of the "on awakening" phenotype.
Clinical manifestation: When network hypersynchronization crosses a threshold sufficient to recruit motor cortex and brainstem tonic/clonic generators (rather than remaining confined to a "typical absence" oscillation), the clinical output is a generalized tonic-clonic seizure rather than absence or myoclonus — the phenotypic differentiator that defines EGTCSA within the IGE spectrum is presumably a difference in network engagement/propagation rather than a wholly distinct etiology.

Molecular pathways: No disease-specific KEGG/Reactome pathway is curated for EGTCSA; relevant general pathways include GABAergic synapse signaling, voltage-gated calcium channel signaling, and glutamatergic (AMPA/mGluR4) signaling within cortico-thalamic circuits.

Cellular processes: Altered neuronal excitability/burst-firing; augmented tonic GABA-A inhibition via astroglial GABA transporter (GAT-1) dysfunction has been demonstrated in GAERS rats and stargazer mice (absence models), raising thalamic ambient GABA and altering tonic inhibition of thalamocortical relay neurons.

Protein dysfunction: Where candidate variants are implicated (e.g., CLCN2), the proposed mechanism is altered channel gating kinetics (faster deactivation) rather than frank loss-of-function or aggregation.

Tissue-level: Neuroimaging in IGE broadly shows subtle structural changes — atrophy in bilateral precentral cortex and thalamus has been reported (PMC11097769); abnormal baseline cerebral blood flow involving basal ganglia/cerebellum circuits has also been described (NBK546611). No gross structural lesion is expected in EGTCSA by definition (idiopathic/genetic, non-lesional).

Immune system involvement: Not implicated; EGTCSA is not classified as an autoimmune or neuroinflammatory epilepsy.

Molecular profiling: No disease-specific transcriptomic, proteomic, or metabolomic signature has been established for EGTCSA in the literature surveyed; GWAS-nominated candidate genes from the 2023 ILAE meta-analysis (29 genes across GGE loci) represent the current state of pathway-level insight (Nat Genet 2023).

Suggested GO terms: - Biological process: "regulation of neuronal synaptic plasticity," "chemical synaptic transmission, GABAergic" (GO:0051932), "regulation of ion transmembrane transport." - Cellular component: thalamocortical relay neuron, thalamic reticular nucleus interneuron (Cell Ontology terms — verify with OAK).

Suggested CL terms: thalamocortical relay neuron, GABAergic interneuron of thalamic reticular nucleus, layer 5/6 pyramidal neuron of somatosensory cortex (from animal-model absence-epilepsy literature; extrapolated to EGTCSA given shared IGE mechanism class — flag as MODEL_ORGANISM-sourced, not directly demonstrated in human EGTCSA tissue).

7. Anatomical Structures Affected

Organ level: - Primary organ: Central nervous system — specifically the thalamocortical network (cerebral cortex + thalamus), rather than a focal lesion. - Body system: Nervous system (UBERON:0001016). - Secondary/complication-related systems: Musculoskeletal (seizure-related fracture/injury), cardiovascular/respiratory (peri-ictal risk relevant to SUDEP — see Outcome section).

Tissue/cell level: - Cerebral cortex (particularly frontal regions — EEG discharges are noted to have "frontal prominence" in generalized IGE, NBK546611) and thalamus (thalamic reticular nucleus, thalamocortical relay nuclei). - Cell types implicated (from mechanistic/animal-model literature, extrapolated): thalamocortical relay neurons, GABAergic reticular thalamic neurons, cortical pyramidal neurons (layers 5/6).

Subcellular level: - Plasma membrane ion channel complexes: voltage-gated T-type calcium channels, GABA-A receptor complex (synaptic and extrasynaptic/tonic), voltage-gated chloride channel (ClC-2). - Suggested GO Cellular Component terms: "GABA-A receptor complex" (GO:1902711), "T-type voltage-gated calcium channel complex," "voltage-gated chloride channel complex."

Localization: Bilateral, diffuse/generalized network involvement (not lateralized) — consistent with the "generalized" designation; EEG and imaging support bilateral, largely symmetric network engagement, though the ILAE 2022 statement and IGE reviews note that "generalized" does not mean uniform involvement of all neurons — specific thalamocortical networks are engaged with sparing of others (PMC11097769).

Suggested UBERON terms: UBERON:0001890 (thalamus), UBERON:0000956 (cerebral cortex), UBERON:0002771 (frontal cortex), UBERON:0001872 (thalamic reticular nucleus, verify exact UBERON ID).

8. Temporal Development

Onset: - Typical age of onset: 10–25 years, with 80% beginning in the second decade of life; overall reported range 5–40 years (epilepsydiagnosis.org; epilepsy.com). - Median age of onset in a prospective cohort (Beydoun 2024, n=89): 16 years. - Onset pattern: Not acute/sudden in the sense of an inciting event — seizures typically begin without an identifiable precipitating illness, though the first seizure is often associated with sleep deprivation (e.g., after an all-nighter, exam period, or party involving alcohol and sleep loss). - A distinct childhood-onset subtype ("childhood-only epilepsy with generalized tonic-clonic seizures") has been described as a well-defined variant with different remission characteristics (Sciencedirect 2019 report, S0920121119300142) — full text was not accessible during this research, but its existence indicates age-of-onset heterogeneity within the broader EGTCSA phenotype.

Progression: - Disease course is generally stable/non-progressive rather than a staged/degenerative process typical of neurodegenerative disorders. - Seizure frequency is typically low (infrequent GTCS) rather than the high-frequency pattern seen in CAE (daily absences) or JME (frequent myoclonus). - Course pattern: Episodic, strongly modulated by state factors (sleep-wake cycle, sleep deprivation, alcohol) rather than continuously active; can be drug-responsive with long stretches of seizure freedom on treatment. - Duration: For many patients the disorder is not lifelong — a substantial fraction achieve durable remission and can discontinue medication (see Outcome section), though relapse after withdrawal is common enough that timing and method of withdrawal materially affect outcome.

Patterns: - Remission: Treatment-associated remission is common; in the Beydoun 2024 cohort, 56% who attempted ASM discontinuation after a median 3 years of treatment maintained seizure freedom, while 44% relapsed. - Critical periods: Adolescence/early adulthood represents the principal period of both seizure onset and diagnostic ascertainment; the "on awakening" chronotype identifies a specific circadian vulnerability window (the 1–2 hours following waking) as a within-day critical period for seizure occurrence.

9. Inheritance and Population

Epidemiology: - IGE as a whole accounts for ~20% of all epilepsies but receives disproportionately little research attention ("less than 1% of scientific literature," PMC11097769/PMID:38165295). - Global epilepsy prevalence (all types): ~65 million people worldwide; active epilepsy prevalence ~6.38 per 1,000 persons; US incidence of generalized epilepsies ~7.7 per 100,000 person-years (NBK546611). - EGTCSA-specific proportions (substantial variability by cohort and diagnostic era): - Classic Janz series: "pure" GTCS-on-awakening epilepsy in ~10% of 4,816 epilepsy patients, with a mixed GTCS + absence/myoclonus phenotype in a further 17%. - Reported range across studies: 0–17% of patients with epileptic seizures. - Among IGE-diagnosed cohorts specifically: 12% of 253 IGE patients in one series; 31% of IGE patients in the Beydoun 2024 prospective cohort (n=89/287 approx.); 65.4% was reported as the most common syndrome in one adult-onset IGE cohort; 5.8% (40/692) in a population-based cohort. - Among a general IGE cohort of 601 patients (Asadi-Pooya & Homayoun 2020, PMID:32030724), 86% (516/601) had GTCS as part of their presentation (not restricted to "alone").

Inheritance pattern: Complex/polygenic — not Mendelian (autosomal dominant/recessive/X-linked/mitochondrial). Genetic counseling is framed around empiric recurrence risk in relatives rather than single-gene transmission probability.

Penetrance/expressivity: Not meaningfully quantifiable under the polygenic model in the way it would be for a monogenic disorder; family members with a positive family history typically manifest other IGE phenotypes (absence, myoclonic, or mixed GTCS syndromes) rather than EGTCSA specifically, consistent with a shared underlying genetic generalized epilepsy liability rather than syndrome-specific inheritance.

Genetic anticipation, germline mosaicism, founder effects: Not established/applicable for this polygenic syndrome; these concepts are more relevant to the rare monogenic mimics that must be excluded.

Consanguinity: Not specifically implicated (consistent with the polygenic, non-Mendelian model — contrasts with recessive monogenic epilepsies where consanguinity is a recognized risk factor).

Population demographics: - Sex ratio: Both sexes equally affected (epilepsydiagnosis.org, epilepsy.com); no strong sex skew reported, unlike some other IGE subtypes. - Geographic distribution: No specific endemic pattern reported; EGTCSA is described across multiple international cohorts (Lebanon/Beydoun, Iran/Asadi-Pooya, European series underlying the ILAE classification), consistent with a globally distributed genetic generalized epilepsy without strong geographic restriction (in contrast to some infection-associated epilepsies). - Age distribution: Concentrated in adolescence/young adulthood at onset (see Temporal Development); a childhood-onset variant is separately described.

10. Diagnostics

Clinical tests / EEG (the primary diagnostic modality): - Interictal EEG: Generalized spike-wave or polyspike-wave discharges at 3–5.5 Hz, seen in about half of patients — often only apparent during sleep. Focal spike-wave can occur but persistent, consistent focal findings should prompt evaluation for a structural lesion. Slow spike-wave activity below 2.5 Hz is absent and its presence suggests an alternative diagnosis (e.g., Lennox-Gastaut spectrum) (epilepsydiagnosis.org EEG page). - Activation procedures: EEG abnormality is enhanced by sleep deprivation, drowsiness, and sleep; generalized spike-wave becomes fragmented (and can spuriously appear focal) under these conditions. An intermittent photoparoxysmal response to photic stimulation may be seen. - Ictal EEG: Often obscured by movement artifact; shows generalized fast rhythmic spikes during the tonic phase, spike bursts time-locked to clonic jerks, followed by post-ictal slow-wave activity. - Diagnostic yield over serial studies (Beydoun 2024): Generalized spike-wave discharges present on the initial EEG in 88% of patients; photoparoxysmal response present in 20% initially, rising to 35% on follow-up EEGs; repeat EEG increased overall diagnostic yield to 96.6% by the second recording — underscoring the value of serial/repeat EEG (including sleep-deprived recordings) when the first study is non-diagnostic. - Background EEG: Normal background with no generalized slowing expected; focal slowing should raise suspicion of a structural abnormality and prompt neuroimaging.

Neuroimaging: MRI/MRA is the standard initial imaging study, primarily to exclude structural lesions — by definition, EGTCSA/IGE shows no lesion on conventional imaging. Research-grade quantitative imaging in the broader IGE literature has described bilateral precentral cortex and thalamic atrophy and altered resting cerebral blood flow (basal ganglia/cerebellar circuits), but these are not part of routine clinical diagnosis.

Genetic testing: Not part of routine clinical evaluation given the polygenic model. Chromosomal microarray is reserved for atypical presentations — specifically drug-resistant EGTCSA or cases with intellectual disability — to screen for recurrent pathogenic CNVs (15q11.2, 15q13.3, 16p13.11 microdeletions).

Clinical diagnostic criteria: Per the ILAE 2022 position statement (Hirsch et al., Epilepsia 2022;63:1475–1499, doi:10.1111/epi.17236), EGTCSA is one of four defined IGE syndromes, diagnosed on the combination of: (1) generalized tonic-clonic seizures as the sole seizure type, (2) EEG showing generalized spike-wave/polyspike-wave activity, (3) age-appropriate onset window, and (4) exclusion of absence and myoclonic seizure types (which would instead point to JAE, JME, or a mixed IGE phenotype).

Differential diagnosis (drawing on general IGE differential, NBK546611): - Focal (impaired-awareness) epilepsy with secondarily generalized tonic-clonic seizures — distinguished by focal EEG onset, longer seizure duration with aura, and (if present) an MRI lesion. - Syncope (cardiac arrhythmia, vasovagal, orthostatic) causing convulsive syncope — ECG and cardiac workup required to exclude. - Psychogenic non-epileptic seizures (PNES) — no EEG correlate; important because 5–40% of PNES patients also have true epilepsy. - GEFS+ spectrum disorders — distinguished by a history of febrile seizures and often (though not always) an identifiable sodium-channel-gene variant. - Other IGE syndromes (JME, JAE) — distinguished by co-occurrence of myoclonic jerks or absence seizures, which by definition exclude "alone" GTCS classification. - De novo absence status epilepticus of late onset — an elderly-onset IGE-spectrum presentation, distinct from EGTCSA's adolescent-onset pattern.

Screening: No population-based or newborn screening program applies (not detectable pre-symptomatically via a defined biomarker); clinical vigilance for a first unprovoked GTCS in the setting of sleep deprivation in an adolescent/young adult is the practical "screening" trigger for EEG referral.

11. Outcome/Prognosis

Treatment response and remission (Beydoun et al. 2024, Epilepsia Open, prospective cohort, n=89): - Seizure recurrence with treatment: 13.5%, versus 73.3% recurrence without treatment (p<0.00001) — demonstrating strong ASM efficacy in this syndrome. - Of 50 patients who attempted ASM discontinuation after a median 3 years of treatment: 56% maintained seizure freedom, 44% experienced recurrence. - Predictors of relapse after withdrawal: patient-initiated (vs physician-directed) tapering, and a mixed circadian seizure pattern (both diurnal and nocturnal seizures) independently predicted higher recurrence risk. - Predictors of successful withdrawal: physician-directed tapering, absence of generalized spike-wave discharges on EEG at the time of withdrawal decision, and a purely diurnal or purely nocturnal (non-mixed) seizure pattern. - One review cites a broader estimate that ~60% of EGTCSA patients recur after medication withdrawal, in a similar range to JME (where recurrence after withdrawal exceeds 75%) but generally less relapse-prone than JME (PMC11097769).

Mortality / SUDEP: - SUDEP (Sudden Unexpected Death in Epilepsy) risk in IGE overall is reported to be broadly similar to focal epilepsy cohorts, although focal epilepsy is more often drug-resistant; uncontrolled GTCS is the single leading SUDEP risk factor, yet notably most SUDEP deaths occur in patients with relatively infrequent GTCS — an important nuance for risk communication (search synthesis from SUDEP literature). Some sources (NBK546611) describe SUDEP risk as lower in IGE compared to other epilepsy categories overall, and lower in females.

Morbidity/complications: - Seizure-related injury risk (fractures, burns, concussion) of 40–60% at 12-month follow-up is reported for recurrent generalized seizures broadly (NBK546611) — directly relevant given EGTCSA seizures are convulsive by definition. - Psychiatric comorbidity contributes to reduced quality of life and (in the broader epilepsy population) to premature mortality, though one large cohort found that after adjustment, only self-harm and substance use disorders (not psychiatric comorbidity broadly) were independently associated with elevated all-cause mortality (PMC9433706). - Drug-resistant course: A subset of IGE patients (up to ~30% cited for JME; comparable figures not isolated for EGTCSA specifically) fail to achieve seizure freedom and require polytherapy or neuromodulation.

Prognostic factors: EEG pattern (presence/absence of GSWD), circadian seizure pattern (pure vs mixed diurnal/nocturnal), and method of ASM withdrawal (physician-directed vs patient-initiated) are the best-documented prognostic modifiers specific to this syndrome (Beydoun 2024).

12. Treatment

Pharmacotherapy — first-line and alternatives: - Valproate (sodium valproate/valproic acid) is the most effective and most commonly prescribed agent for EGTCSA/GTCS-predominant IGE — used in 68.2% of patients in the Beydoun 2024 cohort; broader IGE literature cites ~75% seizure freedom on valproate monotherapy (NBK546611). Valproate additionally prevents absence status epilepticus and is effective in photosensitive patients, but carries significant teratogenicity (7–10% major malformation risk overall; 25.2% risk reported at doses >1,450 mg/day) and is generally avoided in women of childbearing potential when alternatives are viable. - Levetiracetam — second most-used agent in the Beydoun cohort (21.2%); preferred in women of reproductive age due to low teratogenic risk (~1–3%), and generally well-tolerated. - Lamotrigine — effective for GTCS, better-tolerated than valproate, low teratogenic risk; requires slow titration due to Stevens-Johnson syndrome risk, and its metabolism is inhibited by co-administered valproate (requiring dose adjustment). - Topiramate — cited specifically as effective for "tonic-clonic seizures alone" in the IGE spectrum (NBK546611 subtype table). - Phenytoin — used in a small minority (<5%) in the Beydoun cohort, though generally regarded with caution/relative avoidance in IGE broadly. - Perampanel (AMPA receptor antagonist) — used for GTCS, including drug-resistant cases. - Cenobamate (FDA-approved 2019) and brivaracetam — cited as options for drug-resistant IGE/generalized seizures.

Drugs to avoid: - Carbamazepine and oxcarbazepine — documented to worsen myoclonic and absence seizures in the IGE spectrum; may be used cautiously specifically for GTCS-alone presentations in refractory cases but are not first-line. - Phenytoin and vigabatrin — generally contraindicated across IGE.

Non-pharmacological/procedural: - Vagus nerve stimulation (VNS) — well-tolerated option for medically intractable IGE. - Deep brain stimulation (e.g., centromedian thalamic nucleus), responsive neurostimulation, transcranial magnetic stimulation — emerging/investigational neuromodulation approaches for drug-resistant generalized epilepsy. - Ketogenic diet — established since 1921 for refractory epilepsy broadly; in one cited IGE cohort, 48% (41/86 adults) achieved >50% seizure reduction on ketogenic diet.

Supportive/behavioral: - Sleep hygiene counseling (regular sleep schedule, avoidance of sleep deprivation) is a cornerstone of management given the syndrome's defining sensitivity to sleep-wake state. - Alcohol avoidance and general lifestyle counseling regarding seizure precipitants. - Safety counseling: avoidance of unsupervised swimming, heights, and heavy machinery; jurisdiction-specific driving restrictions.

Treatment strategy/withdrawal: Given the recurrence data above, physician-directed (not patient-initiated) tapering, ideally after documented normalization of EEG (loss of GSWD) and a pure (non-mixed) circadian seizure pattern, is the evidence-based approach to attempting ASM discontinuation after a period (median ~3 years in the cited cohort) of seizure freedom.

Suggested NCIT terms for KB curation: NCIT:C15986 (Pharmacotherapy) as the generic treatment_term, with therapeutic_agent bound to CHEBI terms for valproate (CHEBI:39867 valproic acid or its salt form), levetiracetam (CHEBI:6437), lamotrigine (CHEBI:6367), topiramate (CHEBI:9698), perampanel (verify CHEBI ID) — confirm exact CHEBI IDs/labels via OAK before curating. NCIT:C15238 (Gene Therapy) is not applicable; NCIT device/neuromodulation term would apply to VNS (no strong NCIT clinical-action term readily available — verify).

13. Prevention

Primary prevention: No disease-modifying primary prevention exists for the underlying polygenic susceptibility. The practical "primary prevention" applicable to this syndrome is avoidance of known precipitants (sleep deprivation, alcohol, fatigue) in individuals with a known genetic generalized epilepsy predisposition or family history, to reduce the likelihood of triggering a first or subsequent seizure.
Secondary prevention: Early recognition and EEG-based diagnosis after a first unprovoked GTCS (especially in an adolescent following sleep deprivation) allows prompt initiation of ASM therapy, which the Beydoun 2024 data show reduces recurrence from 73.3% (untreated) to 13.5% (treated).
Tertiary prevention: Structured medication management (physician-directed withdrawal timing, EEG-guided decision-making) reduces relapse risk after a period of seizure freedom, as detailed in Outcome/Prognosis above.
Immunization: Not applicable (non-infectious).
Genetic counseling: Given the polygenic/complex inheritance model, counseling for at-risk relatives focuses on empiric recurrence risk rather than single-gene predictive testing; targeted chromosomal microarray is reserved for atypical (drug-resistant or intellectually-impaired) presentations rather than population screening.
Behavioral interventions: Sleep hygiene and alcohol moderation counseling are the most directly evidence-supported prevention measures specific to this syndrome's sleep-wake-triggered phenotype.

14. Other Species / Natural Disease

No naturally occurring veterinary/companion-animal disease specifically corresponding to "epilepsy with generalized tonic-clonic seizures alone" as an ILAE-defined human syndrome was identified in this research. Idiopathic/genetic generalized epilepsy is recognized in domestic dogs (e.g., certain breeds with heritable idiopathic epilepsy showing generalized seizures), but breed-specific correspondence to this exact human syndromic entity was not established in the sources reviewed and should be independently verified (e.g., via OMIA) before curation.

15. Model Organisms

No mouse or other animal model was identified in the literature reviewed that specifically and selectively recapitulates "EGTCSA" as a discrete syndromic entity (i.e., a model producing generalized tonic-clonic seizures as the sole phenotype, on an awakening-linked circadian pattern, without absence or myoclonic seizures). Instead, the field relies on shared thalamocortical/absence-epilepsy models that illuminate the broader IGE mechanism class from which EGTCSA is drawn:

GAERS rats (Genetic Absence Epilepsy Rats from Strasbourg) — genetic model showing spontaneous spike-wave discharges; astroglial GAT-1 dysfunction raises thalamic ambient GABA, altering tonic GABA-A inhibition of thalamocortical relay neurons.
Stargazer mice — stargazin (Cacng2) deficiency causing loss of AMPA receptors at excitatory synapses onto parvalbumin-positive interneurons, implicating glutamatergic feed-forward inhibition failure in spike-wave generation; also show altered GAT-1-mediated thalamic GABA tone (same mechanism family as GAERS).
GABA-A receptor γ2(R43Q) knock-in mice — model absence epilepsy and febrile seizures with abolished tonic inhibition, relevant to the broader GABA-A receptor gene family (GABRG2) implicated across IGE.
Succinic semialdehyde dehydrogenase (SSADH)-deficient mice — show aberrant GABA-A-receptor-mediated inhibition in cortico-thalamic networks, a metabolic-genetic model informative for GABAergic dysfunction mechanisms.

Model limitations relevant to EGTCSA specifically: All of the above are principally absence-seizure models (spike-wave discharge with behavioral arrest), not generalized-tonic-clonic-seizure-predominant models, and none incorporate the sleep-wake/circadian "on-awakening" triggering pattern that clinically defines EGTCSA. This represents a notable translational gap: the mechanistic literature for thalamocortical hypersynchronization is well developed for absence seizures but has not been specifically extended to model the awakening-triggered GTCS-alone phenotype. Any curation connecting these rodent models to EGTCSA pathophysiology should be flagged as MODEL_ORGANISM evidence for the shared IGE/thalamocortical mechanism class, not as direct recapitulation of the EGTCSA clinical syndrome, and a HUMAN_MODEL_MISMATCH-style caveat is warranted given the mismatch between absence-predominant rodent phenotypes and the GTCS-alone human phenotype.

Summary of Key Evidence Gaps for Curation

No monogenic cause — this is a genuinely polygenic syndrome; curators should not force a single causal-gene model.
CLCN2's role is contested (retracted early paper, inconsistent replication) — cite with appropriate hedging/PARTIAL support classification if used.
EGTCSA-specific GWAS/pathway data are sparse — most genomic evidence is at the IGE/GGE class level, not syndrome-specific.
No animal model directly recapitulates the "alone" + "on-awakening" phenotype — available models are absence-epilepsy-focused; use with explicit HUMAN_MODEL_MISMATCH framing.
MONDO ID should be double-checked (MONDO:0005754 vs. a potentially more specific term) and Orphanet ORPHA:698005 confirmed against the live Orphanet record before finalizing identifiers in the KB entry.

Epilepsy with Generalized Tonic-Clonic Seizures Alone

Ask OpenScientist

OpenScientist Report

Mappings

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Diagnosis

Progression

Prevalence

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

Epilepsy with Generalized Tonic-Clonic Seizures Alone (EGTCSA) — Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Evidence Gaps for Curation

Sources